PF-07081532
Protocol C3991003Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 1A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, 
PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY,
AND PHARMACOKINETICS OF MULTIPLE ORAL DOSES OF PF-07081532 IN 
ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS
Study Intervention Number: PF-07081532
Study Intervention Name: N/A
US IND Number:
EudraCT Number: N/A
ClinicalTrials.gov ID:  N/A
Protocol Number: C3991003
Phase: 1
Brief Title: A Phase 1 Study of Multiple Oral Doses of PF-07081532 in Adult 
Participants With Type 2 Diabetes Mellitus
This document and accompanying materials contain confidential information belonging to Pfizer. Except 
as otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this information in confidence and not copy or disclose it to others (except where required by applicable law) 
or use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, Pfizer 
must be promptly notified.
PPDCCI
PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 2Document History
Document Version Date
Original protocol 21October 2021

PF-07081532
Protocol C3991003Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 3TABLE OF CONTENTS
LIST OF TABLES................................................................................................................. ....8
LIST OF FIGURES ................................................................................................................ ...8
1. PROTOCOL  SUMMARY.....................................................................................................9
1.1. Synopsis .................................................................................................................. ..9
1.2. Schema .................................................................................................................... 13
1.3. Schedule of Activities .............................................................................................14
2. INTRODUCTION ...............................................................................................................1 8
2.1. Study R ationale .......................................................................................................18
2.2. Background .............................................................................................................18
2.2.1. Nonclinical Overview.................................................................................18
2.2.1.1. Nonclinical Pharmacology ........................................................182.2.1.2. Nonclinical Pharmacokinetics and Metabolism........................192.2.1.3. Nonclinical Safety .....................................................................20
2.2.2. Clinical Overview.......................................................................................20
2.2.2.1. Clinical Safety...........................................................................22
2.3. Benefit/Risk Assessment.........................................................................................23
3. OBJECTIVES, ENDPOINTS, AND ESTIMANDS ...........................................................254. STUDY DESIGN................................................................................................................ .26
4.1. Overall Design.........................................................................................................264.2. Scientific Rationale for Study Design.....................................................................28
4.2.1. Population(s)...............................................................................................284.2.2. Concomitant Medications...........................................................................284.2.3. Study B linding............................................................................................29
4.2.4. Endpoints ....................................................................................................294.2.5. Collection of Retained Research Samples..................................................30
4.3. Justification for Dose ..............................................................................................304.4. End of Study Definition ..........................................................................................30
5. STUDY POPULATION ......................................................................................................30
5.1. Inclusion Criteria.....................................................................................................30
5.2. Exclusion Criteria....................................................................................................31CCI
PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 45.3. L ifestyle Considerations ..........................................................................................34
5.3.1. Meals and Dietary  Restrictions ...................................................................35
5.3.2. Caffeine, Alcohol, and Tobacco .................................................................36
5.3.3. Activity .......................................................................................................37
5.3.4. Contracepti on
..............................................................................................37
5.4. Screen Failures ........................................................................................................38
6. STUDY INTERVENTIO N(S) AND CONCOMITANT THERAPY .................................38
6.1. Study  Intervention(s) Administered ........................................................................38
6.1.1. Administration ............................................................................................38
6.2. Preparation, Handling, Storage, and Accountability ...............................................39
6.2.1. Preparation and Dispensing ........................................................................40
6.3. Measures to Minimize Bias: Randomization and Blinding
.....................................40
6.3.1. Allocation to Study Intervention ................................................................40
6.3.2. Breaking the Blind ......................................................................................40
6.4. Study  Intervention Compliance ...............................................................................41
6.5. Dose Modification ...................................................................................................41
6.6. Continued Access to Study  Intervention After the End of the Study ......................41
6.7. Treatment of Overdose
............................................................................................41
6.8. Concomitant Therapy ..............................................................................................42
6.8.1. Permitted Medications ................................................................................42
6.8.1.1. Metformin ................................ ................................ .................. 42
6.8.1.2. Antihy pertensive and L ipid-Modify ing Agents ........................42
6.8.1.3. Medications for Management of Nausea and Vomiting ...........42
6.8.2. Pro
hibited Medications ................................ ................................ ............... 42
6.8.2.1. Medications Not Permitted During theStudy  due to 
Potential Drug- Drug Interaction and Other Prohibited, Prior 
and Concomitant Medications ...........................................................43
6.8.3. Rescue Medicine .........................................................................................43
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................43
7.1. Discontinuation of Study  Intervention ....................................................................43
7.1.1. ECG Changes ..............................................................................................44
7.1.2. Adverse Events ...........................................................................................44

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 57.1.3. L aboratory  Abnormalities ...........................................................................44
7.1.4. Potential Cases of Acut e Kidney  Injury .....................................................45
7.1.5. Prohibited Medications ...............................................................................45
7.2. Participant Discontinuation/Withdrawal From the Study .......................................45
7.2.1. Withdrawal of Consent ...............................................................................46
7.3. L ost to Follow -Up...................................................................................................46
8. STUDY ASSESSMENTS AND PROCEDURES ...............................................................47
8.1. Efficacy  Assessments ..............................................................................................49
8.2. Saf ety Assessments .................................................................................................49
8.2.1. Phy sical Examinations ................................................................................49
8.2.2. Vital Signs ..................................................................................................49
8.2.3. Electro cardiograms .....................................................................................50
8.2.4. Clinical Safety  Laboratory  Assessments ....................................................51
8.2.4.1. Fasting Fingerstick Blood Glucose (via Glucometer) ...............51
8.2.4.2. Hy poglycemia Reporting ................................ .......................... 52
8.3. Adverse Events, Serious Adverse Events, and Other Safet y Reporting .................53
8.3.1. Time Period and Frequency  for Collecting AE and SAE Information .......53
8.3.1.1. Reporting SAEs to Pfizer Safety ...............................................54
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF
...................54
8.3.2. Method of Detecting AEs and SAEs ..........................................................54
8.3.3. Follow -Up of AEs and SAEs ......................................................................54
8.3.4. Regulatory
 Reporting Requirements for SAEs ...........................................55
8.3.5. Environmental Exposure, Exposure During Pregnancy  or 
Breastfeeding, and Occupational Exposure .....................................................55
8.3.5.1. Exposure During Pregnancy ......................................................55
8.3.5.2. Exposure During Breastfeeding ................................................57
8.3.5.3. Occupational Exposure .............................................................57
8.3.6. Cardiovascular and Death Events ................................ ............................... 58
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not 
Qualifying as AEs or SAEs ..............................................................................58
8.3.8. Adverse Events of Special Interest
.............................................................58
8.3.8.1. Lack of Efficacy ........................................................................58
8.3.9. Medical Device Deficiencies ......................................................................58

PF-07081532
Protocol C3991003Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 68.3.10. Medication Errors .....................................................................................58
8.4. Pharmacokinetics ....................................................................................................59
8.4.1. Plasma for Analysis of PF-07081532.........................................................598.4.2. Plasma for Analysis of 4- β-hydroxycholesterol/cholesterol ......................60
8.7. Immunogenicity Assessments .................................................................................61
8.8. Health Economics ...................................................................................................618.9. Pharmacodynamics..................................................................................................61
8.9.1. Liquid Meal (for MMTT) ...........................................................................618.9.2. Plasma Glucose, Plasma Insulin, C-Peptide, Glucagon and HbA1c ..........618.9.3. Body Weight...............................................................................................62
9. STATISTICAL C ONSIDERATIONS ................................................................................62
9.1. Statistical Hypotheses .............................................................................................629.2. Analysis Sets ...........................................................................................................629.3. Statistical Analyses .................................................................................................63
9.3.1. General Considerations...............................................................................639.3.2. Primary Endpoint........................................................................................63
9.3.2.1. Electrocardiogram Analyses......................................................64
9.3.3. Secondary Endpoints ..................................................................................649.3.4. Other Analyse(s).........................................................................................66
9.4. Interim Analyses .....................................................................................................679.5. Sample Size Determination.....................................................................................67
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..........................................................................................................68
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............68
10.1.1. Regulatory and Ethical Considerations ....................................................68
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................68
10.1.2. Informed Consent Process ........................................................................69CCI
PF-07081532
Protocol C3991003Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 710.1.3. Data Protection .........................................................................................70
10.1.3.1. Data Monitoring Committee ...................................................70
10.1.4. Dissemination of Clinical Study Data ......................................................7010.1.5. Data Qualit y Assurance ............................................................................71
10.1.6. Source Documents....................................................................................7210.1.7. Study and Site Start and Closure ..............................................................7310.1.8. Publication Policy.....................................................................................7410.1.9. Sponsor’s Qualified Medical Personnel ...................................................74
10.2. Appendix 2: Clinical Laboratory Tests .................................................................7610.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-Up, and Reporting .....................................................................78
10.3.1. Definition of AE .......................................................................................7810.3.2. Definition of an SAE ................................................................................7910.3.3. Recording/Reporting and Follow-Up of AEs and/or SAEs During 
the Active Collection Period............................................................................80
10.3.4. Reporting of SAEs....................................................................................84
10.4. Appendix 4: Contraceptive and Barrier Guidance ................................................85
10.4.1. Male Participant Reproductive Inclusion Criteria ....................................8510.4.2. Female Participant Reproductive Inclusion Criteria.................................8510.4.3. Woman of Childbearing Potential ............................................................8510.4.4. Contraception Methods.............................................................................86
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-Up Assessments .......89
10.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................9110.8. Appendix 8: Prohibited Concomitant Medications That May Result in DDI.......9310.9. Appendix 9: Prohibited Medications Not Permitted From Screening ..................9510.10. Appendix 10: Abbreviations ...............................................................................96
11. REFERENCES ................................................................................................................1 01
CCI
PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 8LIST OF TABLES
Table 1. Overall Visit Schedule and L ist of Procedures (use with Table 2 for 
full details)................................................................................................15
Table 2. Detailed Schedule (selected study  days)...................................................17
Table 3. Completed and Ongoing Clinical Studies .................................................21
Table 4. Populations to be Analy zed......................................................................63
Table 5 Definition of Plasma PK Parameters for PF -07081532 ............................65
Table 6. Protocol -Required Safet y Laboratory  Assessments .................................76
LIST OF FIGURES
Figure 1. Sample Dosing Scheme ............................................................................27

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 91.PROTOCOL SUMMARY 
1.1.Synopsis 
Brief Title: A Phase 1 Study  of Multiple Oral Doses of PF -07081532 in Adult Participants 
With Ty pe 2 Diabetes Mellitus
Rationale
The purpose of this stud y is to evaluate the safet y, tolerability , and PK of multiple doses of 
PF-07081532 in participants with T2DM, inadequately  controlled on metformin. The study  
may also enroll non -diabetic participants with obesity . 
The study  will also assess the effect on PD biomarkers, including MDG .
Objectives , Endpoints ,and Estimands
Objectives Endpoints
Primary: Primary: 
To evaluate the safet y and tolerability  of
multiple doses of PF -07081532, 
administered orall y, in adult participants 
with inadequatel y controlled T2DM on 
metformin and if enrolled, in non- diabetic 
participants with obesity .Assessment of AEs, safety  laboratory  
tests, vital signs and 12 -lead ECGs.
Secondary: Secondary: 
To characterize plasma PK of 
PF-07081532 following multiple doses 
administered orall y, in adult participants 
with inadequatel y controlled T2DM on 
metformin and if enrolled, in non
-diabetic 
participants with obesity .PF-07081532 plasma PK parameters 
AUC 24, Cmax, Tmaxon Day 1 and Day 
42andt½on Day  42, as data permit.
Exploratory: Tertiary: 
To characterize the PD effect on glucose, 
insulin, glucagon, and C -peptide 
excursions after a MMTT following 
multiple doses of PF -07081532, 
administered orall y, in adult participants 
with inadequatel y cont rolled T2DM on 
metformin.CFB in response to MMTT at all 
postdose timepoints as specified in the 
SoA for AUC (0-4)for glucose, insulin, 
glucagon, and C-peptide.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 10Objectives Endpoints
To explore the PD effect on MDG*, 
HbA1c*, plasma glucose, plasma insulin, 
and HOMA -IR following multiple doses 
of PF -07081532, administered orally , in 
adult participants with T2DM 
inadequatel y controlled on metformin and, 
if enrolled, in non -diabetic participants 
with obesity .CFB at all post- dose timepoints as 
specifie d in the SoA for: 
Fasting plasma glucose;
Fasting plasma insulin;
HOMA- IR;
HbA1c *;
MDG *.
To assess the PD effect on body  weight 
changes following multiple doses of 
PF-07081532, administered orall y, in 
adult participants with T2DM 
inadequatel y controlled on metformin and 
if enrolled, in non -diabetic participants
with obesity .CFB in bod y weight at all post -dose 
timepoints as specified in the SoA.
To further characteri ze plasma PK of 
PF-07081532 following multiple doses 
administered orall y, in adult participants 
with inadequatel y controlled T2DM on 
metformin and if enrolled, in non- diabetic 
participants with obesity .Additional PF -07081532 plasma PK 
parameters following multiple dose 
administration including, as data 
permit: AUC 24(dn), AUC inf, AUC last, 
Cav, CL/F, C max(dn), C min, Rac, 
Rac,Cmax , PTR, V z/F
Estimands are not applicable .
*not analy zed in non -diabetic population with obesity , if enrolled .
Overall Design
Brief Summary
This is a Phase 1, randomized, double -blind, sponsor -open, placebo -controlled study  to 
assess the safety , tolerability , and PKof multiple oral doses of PF -07081532 in adult 
participants with ty pe2 diabetes mellitus and in non- diabetic participants with obesity , if 
enrolled.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 11Number of Participants
Within each cohort, approximately  12 participants will be randomized to receive either 
PF-07081532 or placebo (9 PF -07081532: 3 placebo) for a treatment duration of 42 day s 
(approximately  6weeks). 
Intervention Groups and Duration
The duration of the stud y from the Screening visit to the last follow -up visit will be 
approximately  16 weeks , of which 52days will be inpatient at the CRU, followed by  a follow 
up period of 4
-5 weeks, post last dose. Screening may  take up to 28 daysprior to 
randomization. The treatment period with double- blind study  intervention will be once daily, 
for 42 day s.
The study  will begin with 3 planned cohorts and may  be conducted concurrentl y, partiall y 
overlapping or sequentially . Based on emerging data,up to 3 additional cohorts may  be added 
to evaluate additional doses, dos ing schemes, or additional patient population ie, non- diabetic 
participants with obesity . 
A sample 
dosing scheme with dose designations (in mg/day ) for planned cohorts is below. 
The actual doses, treatment sequence and dose increments will be provided to the 
investigator, prior to the start of each cohort.
Data Monitoring Committee or Other Independent Oversight Committee : No
Statistical Methods
Primary  endpoint :clinical safet y laboratory tests, thorough assessments of vital signs and 
12-lead ECGs, ph ysical examinations, and AE monitoring will be performed to provide 
essential data to evaluate the safet y and tolerability of PF -
07081532 .
Secondary endpoints: PK parameters for PF -07081532 including AUC 24, Cmax, Tmaxon Day 1 
and Day 42 and t ½,following multiple dose administration on Day  42will be derived from 

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 12the concentration -time profiles using non- compartmental methods as data permit, and will be 
summarized descriptively.

PF-07081532
Protocol C3991003
Final Protocol, 21October 2021
PFIZER CONFIDENTIAL
Page 131.2.Schema
Dose levels represent PF -07081532 or matching placebo.
Proposed doses; Dosing in Cohort 1 will be conducted as shown ; actual doses , dose increments and dosage duration for 
subsequent cohorts may be adjusted based on emerging data .
Additional cohorts may be added to explore additional doses and dosing schemes 
The cohorts in this study may be run concurrently, partially overlapping or sequentially.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 141.3. S chedule of Activ ities
The SoA table provides an overview of the protocol visits and procedures. Refer to the 
STUDY ASSESSMENTS AND PROCEDURES section of the protocol for detailed 
information on each procedure and assessment required for compliance with the protocol. 
The investigator may  sche dule visits (unplanned visits) in addition to those listed i n the SoA
table , in order to conduct evaluations or assessments required t o protect the well -being of the 
participant .

PF-07081532
Protocol C3991003Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 15Table 1. Overall Visit Schedule and List of Procedures (use with Table 2 for full details)
Protocol Activity Screen Study Day (all activities at 0H [prior to dosing] unless otherwise specified) Follow-Up Early 
Termination Abbreviations used in this table may be found in Appendix 10 .-7 -1 1 2 3-7 8 9-13 14 15-21 22 23-27 28 29 30-35 36 37-41 42 43 44 45 49-56 70-77
a
Outpatient visit (after ≥8-H fast) x x
Informed consent x
Adverse event monitoring x → → → → → → → →→→→→ →→→ → → →→ xx x x
Demography and height x
Inpatient stay at CRU x → → → → → → →→→→→ →→→ →→ → → x
Medical history x x
Review drug, alcohol, tobacco use x x x
Review prior/concomitant treatments x x xx x
Review contraception use/requirement x xx x x
Physical examinationbxx x xx
Body weight x x x x x x x x xx x
COVID-19 questionnairecxx
COVID-19 testingdxx
COVID-19 check temperatureexx x x x x x x xxxx x xxx xx x x xx x x
Supine 12-lead ECGfx
See Table 2
See Table 2xgxx x
See Table 2xx
See Table 2xgxx x x
Supine vital signs (blood pressure and pulse)hxxgxx x x x xgxx x x
Fasting fingerstick blood glucose measurementix x x x x xxxx xxx xx x x
Standardized meals/snacksjx x x x x xxxx xxx xx x x
Liquid meal (for MMTT)k
IP Administration
Blinded IP administrationlxxxxx x x x x x x x
Blood Sampling for:
- Safety laboratory testsmxx x x x x x
- FSH,nHIV, HBsAg, HBcAb, HCVAb, HBsAb x
- Free T4, calcitonin, amylase, lipase, HbA1c, 
TSH, lipidsx x
- Glucose, insulin, C- peptide,mglucagon
- PF-07081532 PK xgxx x x x xoxoxox
-4-β-hydroxycholesterol/cholesterol
Urine Sampling for:
- Urine drug test x x
- Urinalysis (and microscopy, as appropriate) x x x x xx x
PPDCCI
PF-07081532
Protocol C3991003Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 16a. This follow-up contact may be conducted as a phone call.
b. Full physical exam at times indicated; limited exam for previous findings, new/open AEs, or investigator discretion.
c. Enquire about exposure to positive participant, residence or travel in area of high incidence and check for COVID-19 related signs and symptoms.
d. The testing for COVID-19 pathogen by PCR will be performed at Screening and Admission. At Admission, testing will be done prio r to confinement. Additional testing may 
be conducted at the discretion of the investigator.
e. To be done at least daily during residence.
f. Single 12-lead ECG at Screening, follow-up and Early Termination (if applicable). Measure in triplicate at all other times in dicated.
g. Measurement/sample at 0H corresponds to the 24H timepoint as detailed in Table 2 (ie, listed in both tables, but only one sample/measurement should be collected).
h. Single vital signs at Screening, follow-up and Early Termination (if applicable). Measure in triplicate at all other times in dicated.
i. Fingerstick glucose via glucometer on admission to CRU and prior to breakfast on all inpatient days; may be more frequent at the discretion of the investigator.
j. Meals to be provided on all days while inpatient at approximately 0H, 4H, and 10H relative to dosing; snacks may be provided. Refer to Section 5.3.
k. This procedure is to be conducted in participants enrolling with T2DM only.l. Dose administration to occur with breakfast or liquid meal daily on Days 1 to 42, inclusive, see Section 5.3 and Section 6 .
m. See Appendix 2 for safety lab tests to be collected at each timepoint, see Section 5.3 for fasting requirements. Note: C-peptide is co llected as part of safety labs at Screening.
n. FSH in females to confirm postmenopausal status only.
o. PK samples on Day 43, 44, and 45 are to be collected 24H, 36H, 48H, and 72H after the final PF-07081532 dose on Day 42.
PPD
PF-07081532
Protocol C3991003Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 17Table 2. Detailed Schedule (selected study days)
Study Day Hours Relative to Dosing at 0Ha
0 0.25 0.5 1 1.5 23468 1 0 1 2 1 6 2 4b
Triplicate, supine 12-lead ECG Days -1, 1, and 42 x xxxxx x
Triplicate, supine vital sign (blood pressure and pulse) Days -1, 1, and 42 x xxxxx x
Fasting fingerstick blood glucose measurementb,cAll inpatient days x
Liquid meal (for MMTT)dDays -1, 28eand 42 x
Standardized meal/snackfall inpatient days xgxx x
Blinded investigational product administration Daily: Day 1 to Day 42 xh
Blood sampling for:
- Safety laboratory testsiDays -1, 28, and 42 xj
- HbA1ck, TSH Days -1, 28, and 42 xj
- Plasma glucoselDays -1, 28eand 42 xjx xxxxxxxxxxx x
- Plasma insulinlDays -1 and 42 xj, mx xxxxxx
- Plasma C- peptidek, glucagonk) Days -1 and 42 xjx xxxxxx
- Free T4, calcitonin, amylase, lipase, lipids Days -1, 28, and 42 xj
-PF-07081532 PK Days 1 and 42 x x x x xxxxxx x
-4 -β-hydroxycholesterol/cholesterol Days 1 and 42 x
- Retained research samples for Prep D1.5 Day -1 onl ynx
- Retained research samples for Prep B1.5 and Prep B2.5 Day -1 and Day 42 x
Urine sampling for:
- Urinalysis and microscopy, as appropriate Days -1, 28, and 42 x
a. On Day -1, time of 0H procedures to match approximate planned clock time of collection on Day 1. All other days, 0H procedures to be completed pre-dose.
b. The 24H sample is to be collected prior to dosing on the following morning, as indicated in Table 1 .
c. Fingerstick glucose via glucometer on admission to CRU and prior to breakfast on all inpatient days; may be more frequent at t he discretion of the investigator.
d. Liquid meal given at 0H (or on Day -1 at the anticipated clock time of Day 1 dose) to be consumed over 10 mins. The 0.25 H sampl e is 5 minutes after completion of the 
liquid meal. This procedure is to be conducted in participants enrolling with T2DM only.
e. Indicated procedures will be conducted on Days -1, 28, and 42 for Cohort 1; decision for Day 28 procedures in subsequent cohor ts will be provided in writing prior to 
initiation of dosing for each cohort.
f. Standardized meals/snacks to be provided on all days while inpatient; identical meals/snacks on days when MMTT is being condu cted. Refer to Section 5.3 .
g. Standard breakfast NOT provided on days when MMTT is being conducted; refer to Section 5.3 .
h. Dosing to occur with breakfast or liquid meal daily from Day 1 to day 42, inclusive.i. See Appendix 2 : Clinical Laboratory Tests for safety lab tests to be collected at each timepoint.
j. See Section 5.3 for fasting requirements. 
k. Participants enrolling with T2DM only.
l. Fasting (0H) sample is to be collected in all participants. Post-dose timepoints in participants enrolling with T2DM only.
m. Fasting (time 0H only) insulin to be measured in triplicate on Day -1 and Day 42, all other measurements single, see Section 8.9.2 .
n. If not collected on the designated collection day, collect at the next available time point when biospecimens are being collect ed in conjunction with a participant visit.
PPD
PF-07081532
Protocol C3991003Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 182. INTRODUCTION
GLP-1 is a neuroendocrine hormone that is predominantly released from the small intestine 
in response to food intake.1Activation of the GLP-1R stimulates insulin release, inhibits 
glucagon secretion in a glucose-dependent manner, and delays gastric emptying.2,3In 
addition, GLP-1 has been shown to increase satiety and suppress food intake.4
PF-07081532 is a potent and selective, orally administered, small molecule GLP-1R agonist that is being developed as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. 
2.1. Study Rationale 
The purpose of the study is to evaluate the safety, tolerability and PK of multiple doses and 
different dosing schemes of PF-07081532 in participants with T2DM, inadequately controlled on metformin and, if enrolled, in non-diabetic participants with obesity. 
The study will also assess the effect of PF-07081532 on PD biomarkers, including MDG in 
participants with T2DM.
2.2. Background 
Diabetes is estimated to affect approximately 425 million adults (8.8% of people aged 
20-79 years) world-wide.
5,6. The increase in the global prevalence of T2DM is largely 
attributed to rising rates of excess body weight and obesity.7
T2DM is characterized by insulin resistance, a disorder in which cells do not respond effectively to insulin, resulting in higher blood glucose levels. Elevated blood glucose levels and increasing severity of insulin resistance result in the need for more insulin over time, 
eventually resulting in progressive pancreatic β-cell failure.
8Patients with poorly controlled 
T2DM have an increased risk of developing complications associated with both microvascular and macrovascular disease, including nephropathy, neuropathy, retinopathy, cardiovascular disease and stroke, and are at 2 to 4 times increased risk of mortality than adults who do not have diabetes.
9While existing pharmacological options for the treatment 
of diabetes may provide satisfactory glycemic control for some patients, there remain many patients who do not achieve target HbA1c levels, suggesting a need for additional therapeutic options. 
Based on the clinical history of injectable GLP-1R agonists, an oral GLP-1R agonist is 
expected to improve glucose control and reduce HbA1c levels in patients with T2DM, while decreasing food intake and body weight and avoiding the subcutaneous injection required by a majority of currently available peptidic GLP-1R agonists.
2.2.1. Nonclinical Overview
2.2.1.1. Nonclinical PharmacologyIn vitro primary pharmacodynamic studies demonstrated that in cells expressing recombinant 
human and monkey GLP-1R, PF-07081532 promotes cAMP production.  
CCI
PF-07081532
Protocol C3991003Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 19 
. PF-07081532 was shown to bind to the 
human GLP-1R using a competition binding assay. In vivo, PF-07081532 potentiated glucose-stimulated insulin secretion during an IVGTT in cynomolgus monkeys at plasma exposures that were consistent with its in vitro potency.
Details of the nonclinical pharmacology program are included in the IB.2.2.1.2. Nonclinical Pharmacokinetics and Metabolism
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
PF-07081532
Protocol C3991003Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 20 
 
 
Further details of the nonclinical pharmacokinetics and metabolism program are included in 
the IB.
2.2.1.3. Nonclinical Safety
PF-07081532 was evaluated in genetic toxicity studies and oral, repeat-dose rat and 
cynomolgus monkey toxicity studies as well as cardiovascular and neuropulmonary safety pharmacology studies.  
 
 
In the 8-week oral gavage toxicity study conducted in cynomolgus monkey at 20, 60, and 
100 mg/kg/day, no adverse effects were detected and the NOAEL was defined as the high dose of 100 mg/kg/day.  
A 6-week oral gavage toxicity study was conducted in Wistar Han rats with PF-07081532 
and the intermediate dose of 100 mg/kg/day was considered to be the NOAEL
. Details of both studies can be found in the IB.
Safety pharmacology studies conducted to assess potential pharmacodynamic effects on 
central nervous and respiratory systems did not identify any effects at doses up to 300 mg/kg in rats.  
 
 
 
 
 
PF-07081532 was not mutagenic or clastogenic both in vitro and in vivo (rat micronucleus 
study) and was negative for phototoxic potential.
2.2.2. Clinical Overview
The safety of PF-07081532 has been assessed in 1 completed clinical Study C3991001, and 
is being assessed in 1 ongoing clinical Study C3991002.CCI
CCI
CCI
CCI
CCI
PF-07081532
Protocol C3991003Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 21Table 3. Completed and Ongoing Clinical Studies
Study 
IdentifierStudy Design and Type of 
ControlDosing Regimen, 
Formulation DoseNumber of 
Participants 
RandomizedPopulation Treatment Duration Study Status
C3991001 Phase 1, double-blind, 
randomized, placebo controlled, 
single ascending dose study. Two interleaving cohorts of healthy adult participants with crossover, placebo substitution design. 
One cohort of healthy adult 
Japanese participants with 
crossover placebo substitution design.PF-07081532 or 
placebo. 
Orally administered 
solution 
Dose Range: 10 mg 
to 200 mgPF-07081532: 22 
Placebo: 12Healthy 
Adult 
ParticipantsSingle dose Completed
C3991002 Phase 1, randomized, 
double-blind (investigator- and participant-blind), sponsor-open, placebo-controlled, multiple oral 
dose-escalating study.Orally administered 
tablet 
Part A: 10 
(8 PF-07081532: 2 placebo) planned participants/cohortMultiple doses Ongoing: 
dosing completed, data analysis and reporting ongoing
Target dose range: PF-07081532 10 mg to 180 mg or 
placeboAdult 
Participants with T2DM28 days’ dosing
Target dose 
PF-07081532 180 mg or placeboPart B: 15
(12 PF-07081532: 3 placebo) planned participants/cohortAdult 
Participantswith Obesity42 days’ dosing
Target dose 
PF-07081532 
180 mg or placeboPart C: 10
(8 PF-07081532: 2 
placebo) planned participants/cohortAdult 
Participants 
with T2DM42 days’ dosing
PPD
PF-07081532
Protocol C3991003Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 222.2.2.1. Clinical Safety 
Clinical data for the completed study, C3991001, are provided in the current version of the 
IB. 
A blinded summary of currently available data from study C3991002 is provided below. 
These data should be considered preliminary and subject to update on final reporting of the study’s results. PF-07081532 or matching placebo have been administered to a total of 51 participants with T2DM and 15 participants with obesity. A dose titration approach was used, where doses within a cohort were titrated up to a target dose over the dosing period.The duration of titration varied across cohorts. The target doses ranged from 10 mg (no titration phase) to 180 mg PF-07081532 or matching placebo. Each cohort was expected to receive study drug at the target dose level for a minimum stable dosing period of 7 days.
Four cohorts of participants with T2DM have been randomized to receive doses of 
PF-07081532 (target doses of 10 mg to 120 mg) or matching placebo once daily for 28 days.One cohort of 10 participants with T2DM has been randomized to receive PF-07081532 titrated to a target dose of 180 mg, or matching placebo, once daily for 42 days. One cohort of 15 participants with obesity has been randomized to receive PF-07081532 titrated to a target dose of 180 mg or matching placebo once daily for 42 days. One participant who completed dosing (blinded target dose 30 mg/placebo) experienced an SAE of acute gallstone pancreatitis during the follow-up period. The investigator reported that there was a reasonable possibility that the event was related to blinded study drug. The totality of available data, including medical history, has been reviewed by the Sponsor. The overall evidence, in the opinion of Sponsor, points to gallstone, rather than drug-induced pancreatitis, as the likely cause of this event. There was no change to the benefit/risk profile of PF-07081532, nor was any change to the conduct of the ongoing clinical study judged to be required. 
A majority of TEAEs reported have been mild in severity. The most frequently reported 
TEAEs have been in the GI system as consistent with reports for marketed GLP-1R agonists.While there have been isolated values for laboratory tests, vital signs and ECG intervals outside of the reference ranges, no clear adverse trends were apparent in these parameters. As has been reported for marketed GLP-1R agonists,
10,11a trend toward modest increases in 
heart rate has been observed, with most heart rate values within the normal range.
 
 
 
 
 
 
 
 
 
PPDCCI
PF-07081532
Protocol C3991003Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 23 
 
 
2.3. Benefit/Risk Assessment
This study is designed primarily to generate safety, tolerability, and PK data from adult 
participants with T2DM and, potentially, participants with obesity and without T2DM. The purpose of the study is to provide the basis for further clinical development of PF-07081532 as a potential new, pharmacological agent for the treatment of T2DM. 
Based on the clinical history of injectable GLP-1R agonists, an oral GLP-1R agonist is 
expected to improve glucose control, reduce HbA1c levels, diminish food intake, and decrease body weight in patients with T2DM, while avoiding the requirement for subcutaneous injections that accompany a majority of currently available peptidic GLP-1R agonists.
As of the issuance of this protocol, no specific human risks associated with PF-07081532 
administration have been identified. The doses being evaluated in this study are anticipated to be in the range of doses previously tested. Data gathered during nonclinical and clinical studies with PF-07081532 to date are summarized in the current IB and in Section 2.2 . 
Potential Risk of 
Clinical SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Study Intervention – PF-07081532
Potential risks 
associated with marketed GLP-1Ragonists including thyroid C-Cell tumors, pancreatitis, changes in 
heart rate and blood 
pressureThe potential risks are based on 
product labeling for marketed GLP-1R agonists (liraglutide, dulaglutide, and exenatide); additional information is provided in the current IB.•Study includes inpatient 
monitoring of the participants following administration of multiple, oral doses of the investigational product. 
•Potential participants with a 
personal or family history of 
medullary thyroid carcinoma or MEN2 are not eligible for study entry. Potential participants with acute pancreatitis or a history of 
chronic pancreatitis are not 
eligible for study entry.
•Clinical safety laboratory tests, 
including thyroid function, serum amylase and lipase, thorough assessments of vital signs and 
ECGs, physical examinations and 
adverse event monitoring will be undertaken throughout the dosing 
period.
Gastrointestinal adverse eventsThe potential risks are based on 
product labeling for marketed GLP-1R agonists (liraglutide, exenatide and Participants are monitored during the 
study to prevent potential sequelae of any severe gastrointestinal reactions, CCI
PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 24Potential Risk of 
Clinical SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
dulaglutide). In addition, 
gastrointestinal AEs, the majority of 
which were mild in severity, have been 
observed in the clinical program with 
PF-07081532 to date.eg, dehydration. Concomitant 
medication for nausea is permitted in 
the study
Other Factors Potentially Impacting Study Results
Risk of COVID -19 
exposureN/A All participants will be tested for 
COVID -19 and confirmed negative, 
prior to admission to the site; once 
admitted, all participants will be 
monitored daily for COVID -related 
symptoms, including fever
More detailed information about the known and expected benefits and risks and reasonabl y 
expected AEs of PF -07081532 may  be found in the curr ent version of the IB, which is the 
SRSD for this study .
Considering all available clinical and nonclinical data, the benefit -risk profile of 
PF-07081532 supports continued clinical development.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 253.OBJECTIVES , ENDPOINTS , AND ESTIMANDS
Objectives Endpoints
Primary: Primary: 
To evaluate the safet y and tolerability  of
multiple doses of PF -07081532, 
administered orall y, in adult participants 
with inadequatel y controlled T2DM on 
metformin and ,if enrolled, in non -diabetic 
participants with obesity .Assessment of AEs, safety  laboratory  
tests, vital signs and 12 -lead ECGs.
Secondary: Secondary: 
To characterize plasma PK of 
PF-07081532 following multiple doses 
administered orall y, in adult participants 
with inadequatel y controlled T2DM on 
metformin and ,if enrolled, in non -diabetic 
participants with obesity .PF-07081532 plasma PK parameters 
AUC 24, Cmax, Tmaxon Day 1 and Day  
42 and t ½on Day  42, as data permit.
Exploratory: Exploratory: 
To characterize the PD effect on glucose, 
insulin, glucagon, and C -peptide 
excursions after a MMTT following 
multiple doses of PF -07081532, 
administered orall y, in adult participants 
with inadequatel y controlled T2DM on 
metformin .CFB in response to MMTT at all 
postdose timepoints as specified in the 
SoA for AUC (0-4)for glucose, insulin, 
glucagon, and C -peptide.
To explore the PD effect on MDG *, 
HbA1c *, plasma glucose, plasma insulin, 
and HOMA -IR following multiple doses 
of PF -07081532, administered orally , in 
adult participants with T2DM 
inadequatel y controlled on metformin and ,
if enrolled, in non -diabetic participants
with obesity .CFB at all post
-dose timepoints as 
specified in the SoA for: 
Fasting plasma glucose;
Fasting plasma insulin;
HOMA- IR;
HbA1c *;
MDG *.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 26Objectives Endpoints
To assess the PD effect on body  weight 
changes following multiple doses of 
PF-07081532, administered orall y, in 
adult participants with T2DM 
inadequatel y controlled on metformin and ,
if enrolled, in non -diabetic participants
with obesity .CFB in bod y weight at all post -dose 
timepoints as specified in the SoA.
To further characterize plasma PK of 
PF-07081532 following multiple doses 
administered orall y, in adult participants 
with inadequatel y controlled T2DM on 
metformin and ,if enrolled, in non -diabetic 
participants with obesity .Additional PF -07081532 plasma PK 
parameters following multiple dose 
administration including, as data 
permit: AUC 24(dn), AUC inf, AUC last,
Cav, CL/F, C max(dn), C min, Rac, 
Rac,Cmax , PTR, Vz/F.
Estimands are not applicable.
*not analy zed in non -diabetic population with obesity , if enrolled .
4.STUDY DESIGN
4.1.Overall Design
This is a randomized, double -blind (investigator -and participant -blind), sponsor -open, 
placebo- controlled, multiple oral dose -escalating study  of PF -07081532. 
In this stud y, adult participants with T2DM inadequately controlled on metformin will be 
enrolled and will receive PF- 07081532 or placebo daily , for 42 days. 
Enrollment in 3 cohorts is planned with approximately 12 participants 
(9PF-07081532: 3 placebo) per cohort. 
A sample dosing scheme is provided below. Dosing in Cohort 1 will be conducted as shown. 
Increments in doses and duration of dosing at each step for subsequent cohorts, as well as the 
number of cohor ts conducted, may  be adjusted based on emerging data. The dosing scheme 
for each cohort will be provided in writing prior to its initiation. 

PF-07081532
Protocol C3991003
Final Protocol, 21October 2021
PFIZER CONFIDENTIAL
Page 27Figure 1.Sample Dosing Scheme
If a participant does not tolerate dose increment to the next dose level, as determined b y the 
investigator and with notification to the sponsor, the participant may be reverted to the 
previously  tolerated dose level. Following this dose modification, 2 separate attempts at 
increasing the dose to the next dose l evel are permitted, per investigator discretion. If, per 
investigator assessment, unacceptable intolerance (eg, severe vomiting) occurs shortly 
following dose administration, the dose will not be re -administered on the same day , and the 
participant may  resume dosing at the current dose level at the next scheduled dosing time. 
Participants whose dose level is tolerability -limited may  continue in the study  for the 
intended duration of their assigned cohort at their own individual MTD, as judged to be 
appropri ate b y the PI  and sponsor.
The planned cohorts in the study  (Cohorts 1 -3) may be conducted concurrently , partiall y 
overlapping or sequentially .The sponsor may  decide not to conduct all planned cohorts, if it 
is judged that stud y objectives have been met. Up to 3 additional cohorts may be enrolled if 
judged necessary  to me et the study  objectives. One or more of the study  cohorts may be 
conducted in non
-diabetic participants with o besity , see Section 4.2.1 and Section 5.
Determination of eligibility  will oc cur within 28 day s of randomization based on criteria 
including medical history, vital sign, ECG and laboratory  parameters, as detailed in 
Section 5. Participants deemed eligible will be admitted to the CRU 7days prior to start of 
dosing (Day  -7) and will remain on- site until at least Day  45, post first dose . 
The treatment period with double -blind study  intervention will be 42 day s, with study  drug 
administered once daily . The participants within a given cohort will be blinded to the study  
treatment ( PF-07081532 versus placebo). Participants who discontinue prior to completion of 
the study  may  be replaced, at the discretion of the PI  and sponsor.
Upon discharge from the CRU, participants will return to the CRU 7 to 14 days after the last 
administration of I P for an on -site follow -up visit. A further follow -up contact with 
participa nts will be conducted at least 28 days and up to 35 days after the last administration 
of IP; this contact may  be done via a phone call.

PF-07081532
Protocol C3991003Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 28The total duration of the study from the Screening visit to the last follow-up visit will be 
approximately 16 weeks of which 52 days will be inpatient at the CRU, followed by a follow-up period of 4-5 weeks, post last dose.
The study will be conducted in the USA. 4.2. Scientific Rationale for Study Design
The primary objective of the study is to evaluate the safety and tolerability of multiple doses 
of PF-07081532 administered with different doses and dosing schemes over 42 days in participants with T2DM, inadequately controlled on metformin. Due to the gastrointestinal-related tolerability issues associated with GLP-1 receptor agonism
12that 
have been shown to tolerate with repeated dosing, this study will evaluate safety and tolerability of different starting doses and titration increments in order to optimize the titration schemes for studies of longer duration.
4.2.1. Population(s)
Participants enrolled in this study will be adults with inadequately controlled T2DM (as 
indicated by HbA1c at screening) on metformin monotherapy, which is considered first-line therapy for glycemic control according to current treatment guidelines.
13At screening, this 
study requires that participants with T2DM have been taking a minimum stable metformin dose of at least 500 mg/day for at least 2 months prior to the screening visit. The dose of metformin, where possible, is expected to remain the same until completion of study participation (ie, follow-up visit). Available in vitro data suggest that PF-07081532 is not expected to impact the PK of metformin via inhibition of OCT2, and the risk of a clinical interaction is deemed negligible. One or more cohorts of non-diabetic participants with obesity may be enrolled in this study. The safety, tolerability, PK and PD data collected in this study may be used to select doses and dosing scheme algorithms for future studies of PF-07081532.
The population planned for this study will be male and female adult participants. Female 
participants will be WONCBP, since at the present time embryofetal development toxicity studies with PF-07081532 have not been conducted. In male participants appropriate measures are expected to be followed to limit potential transfer of PF-07081532 in semen to partners (see Appendix 4 ).
4.2.2. Concomitant Medications
 
 
 
 
 
For more 
information regarding concomitant medications in this study, see Section 6.8 .
CCI
PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 294.2.3. Study Blinding
To permit an unbiased assessment of safet y,the pa rticipants’ treatment assignments 
(PF-07081532 versus placebo, but not cohort designation ) will be blind to both site staff 
(except those involved in preparation of doses) as well as the study  participants. However, to 
permit real -time review of the safet yand PK data, a limited number of sponsor study  team 
members will be unblinded (see Section 9.4).
4.2.4. Endpoints
Clinical safety  laboratory tests, thorough assessments of vital signs and 12 -lead ECGs, 
physical examinations, and AE monitoring will provide essential data to evaluate the safet y 
and tolerability  of PF -07081532. To supplement standard clinical safety laboratory  tests, 
calcitonin, am ylase, lipase, TSH, T4 and lipid panel will be assessed based on the study  
population and guided b y data available on marketed GL P-1R agonists.12In addition, TBA 
will be assessed, based on non- adverse findings in the nonclinical studies with PF -07081532 
(see Section 2.2.2 and the IB ).
While GL P
-1R agonists ty pically  are not associated with hy poglycemia unless co-
administered with anti- diabetic agents that can cause hy poglycemia (such as insulin or
sulfony lureas), blood glucose concentrations will be monitored throughout the study  via a
glucometer at least once daily  (pre-breakfast), and careful monitoring of s ymptomatic
hypoglycemic AEs will be performed.
In an effort to reduce variability  and better quantify any potential changes in heart rate and
BP during the study , all measurements of ECG and vital signs (pulse and BP) will be 
collected in triplicate (except as noted in the SoA) and the mean values will be used for 
analysis at each time point.
The effect of PF-07081532 on glucose response in participants with T2DM will be evaluated 
by determining the change from baseline in MDG. Since MDG is the time -averaged response 
over a day , it is expecte d that this gly cemic parameter will be predictive of longer term 
glycemic control. The effect of PF -07081532 on body  weight, FPG and other gly cemic 
markers including insulin, C- peptide, HbA1c, and glucagon will also be assessed. FPG and 
FPI levels will be assessed and used to calculate HOMA -IR. In order to reduce variability  in 
FPI for HOMA -IR calculation,14triplicate measurements will be collected as indicated in the 
SoA and Section 8.9.2. In an effort to reduce variability , minimize any  potential effect of 
placebo or CRU confinement 
and better quantify  any potential changes to these parameters, 
the participants will be admitted to the CRU on Day - 7 in order t o monitor compliance with 
background metformin and recommended diet.
Baseline (Day  -1) assessments with time -matched procedures will permit within participant 
comparisons, as appropriate. In addition, placebo- adjusted (between participant ) comparisons 
of dose-response will also be conducted. 

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 304.2.5. Collection of Retained Research Samples
Retained Research Samples will be collected and stored for further anal yses which may , for 
example, provide understanding of the study  intervention.
4.3.Justification for Dose
Doses for the stud y will be determined considering all relevant information obtained from 
nonclinical safet y studies along with safet y, tolerability , and PK data observed in completed 
study  C3991001, ongoing Study  C3991002 and emerging data from prior cohorts of this 
study , as applicable. The dose levels to be assessed in this study  are anticipated to be within 
the dose range evaluated in C3991002 (10 mg to 180 mg QD), where no safety  concerns with 
PF-07081532 have been identified. The total duration of dos ing for PF- 07081532 or placebo 
in this study  will be 42 days, as supported by  completed nonclinical toxicity  studies (see 
Section 2.2.1.3 ).
Cohort 1 will receive PF-07081532 20 mg, or placebo, QDfor 28 days followed by  60mg or 
placebo, QDfor the remaining 14 day s. Th is was selected to assess whether a starting dose of 
20mg QD offers a profil e that will allow its use as the initial titration step in future longer 
duration studies. The dosing schemes in subsequent c ohorts may  be adjusted based on 
emerging data in order to generate valuable information (eg , on different starting doses or 
dose in
crement steps) that will enable optimization of the dosing schemes for use in future 
studies. The doses and dose increments will be selected for this study  in order to obtain data 
on these initial steps and not to necessaril y reach the target doses where efficacy  of 
PF-
07081532 could beevaluated in future studies of longer duration .
4.4.End of Study Definition
The end of the stud y is defined as the date of the last visit of the last participant in the study  
or last scheduled procedure shown in the SoA for the last participant in the trial globall y.
A participant is considered to have completed the study  if he/she has completed all periods of 
the study , including the last visit or the last scheduled procedure shown in the SoA.
5.STUDY POPULATION
This study  can fulfill its objectives only  if appropriate participant s are enrolled. The 
following eligibility  criteria are designed to select participant s for whom participation in the 
study  is considered appropriate. All relevant medical and nonmedical conditions should be 
taken into consideration when deciding whether a particular participant is suitable for this 
protocol .
Prospective approval of protocol deviations to recruitment and enrol lment criteria ,also 
known as protocol waivers or exemptions, is not permitted .
5.1.
Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 31Age and Sex :
1.Male and female participants must be between the ages of 18 and 70 years, inclusive, 
at the time of signing the ICD. 
2.Females must be of non childbearing potential.
Refer to Appendix 4 for reproductive criter ia for male s (Section 10.4.1) and 
female s
(Section 10.4.2) participants.
Type of Participant and Disease Characteristics:
3.
Patients with T2DM who are treated with metformin.
Note: Participants must be taking metformin monotherapy  as their onl y anti-
hypergly cemic treatment. Metformin dose must be at least 500 mg per day and must 
be stable, defined as no change in the treatment and participant -reported compliance 
with treatment , for at least 2 months prior to the screening visit.
4.HbA1c ≥7.0% and ≤10.5% at screening (confirmed by  a single repeat, if necessary ). 
Note: For non-diabetic participants with obesity (if enrolled), HbA1c <6.5% at 
screening. 
5.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, lifesty le considerations, and other study  procedures.
Weight and BMI:
6.Total body  weight >50 kg (110 lbs) and BM I ≥24.5 to ≤45.5 k g/m2.
Note: For non-diabetic participants with obesity (if enrolled) BMI >30.5 to 
≤45.5 kg/m2.
Informed Consent:
7. Capable of giving signed informed consent as described in Appendix 1 ,which 
includes compliance with the requirements and restrictions listed in the ICDand in 
this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Evidence or history  of clinically  significant hematological, renal, endocrine, 
pulmonary , gastrointestinal, hepatic, ps ychiatric, neurological, dermatological, or 

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 32allergic disease (including drug allergies but excluding untreated, as ymptomatic, 
seasonal al lergies at the time of dosing).
Participants who have chronic conditions other than T2DM and obesit y (for 
example, hy percholesterolemia or hy pertension) but are controlled b y either diet 
or stable doses of 2 or fewer medications may  be included (for exampl e, a 
participant with hypercholesterolemia on appropriate treatment is eligible). See
Section 6.8 for further information on concomitant medications.
For non -diabetic participants with obesity (if enrolled), a medical history  of 
T2DM .
2.Diagnosis of t ype1 diabetes mellitus or secondary  forms of diabetes.
3.Evidence or history  of clinically  significant cardiovascular disease. In particular, 
history  of m yocardial infarction, unstable angina, arterial revascularization, stroke, 
New York Heart Association Functional Class II -IV heart failure, o r transient 
ischemic attack within 6 months of screening.
4.Any malignancy  not considered cured (except basal cell carcinoma and squamous cell 
carcinoma of the skin); a participant is considered cured if there has been no evidence 
of cancer recurrence in the previous 5 years.
5.Acute pancreatitis or history  of chronic pancreatitis.
6.Acute gallbladder disease. 
7.Any condition possibly  affecting drug absorption (eg, prior bariatric surgery , 
gastrectom y, or an y area of intestinal resection, active inflammatory  bowel disease or 
pancreatic insufficiency ).
8.Personal or famil y history of MTC or MEN2, or participants with suspected MTC per 
the investigator’s judgement.
9.Other medical or psy chiatric condition including recent (within the past y
ear) or 
active suicidal ideatio n/behavior or laboratory  abnormality  that may  increase the risk 
of study  participation or, in the investigator’s judgment, make the participant 
inappropriate for the study .
Prior/Concomitant Therapy:
10.Participants who have received any  vaccin e within the 1 week prior to admission to 
the CRU .
11. U se of an y prohibited concomitant medication(s) or those unwilling/unable to use a 
permitted concomitant medication(s). Refer to Section 6.8andAppendix 8 .

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 33Prior/Concurrent Clinical Study Experience:
12.Previous administration with an investigational drug within 30 days (or as determined 
by the local requirement) or 5 half-lives preceding the first dose of study  intervention
used in this study  (whichever is longer).
13.Known prior participation (ie, randomized and received at least 1 dose of 
investigational product) in a trial involving PF -07081532. Note that a given 
individual may  only participate in one cohort of this study .
Diagnostic Assessments:
14. A positive urine drug screen at screening or admission.
Note: Participants who have been medicall y prescribed benzodiazepines and report 
the use of these drugs to the investigator at the screening visit may  be allowed to 
participate if approved by the sponsor.
15.Positive testing at screening for HIV, HBsAg, HBcAb, HBsAb orHCVAb . Positive 
COVID -19test at screening oradmission .
Note: A positive HBs Ab due to hepatitis B vaccination is permissible.
16.Screening supine BP ≥160 mm Hg (s ystolic) or ≥100 mm Hg (diastolic) following at 
least 5 minutes of supine rest. 
If BP is ≥160 mm Hg (s ystolic) or ≥100 mm Hg (diastolic), the BP should be 
repeated 2 more times and the average of the 3 BP values should be used to determine 
the participant’s eligibility.
17.Screening 12- lead ECG that demonstrates clinically  relevant abnor malities that may  
affect participant safet y or interpretation of stud y results (eg, baseline QTcF interval 
>450 msec, complete LBBB, signs of an acute or indeterminate -age m yocardial 
infarction, ST -T interval changes suggestive of my ocardial ischemia, seco nd-or 
third
-degree AV block, or serious brad yarrhythmias or tachy arrhy thmias).
If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 
2more times and the average of the 3 QTcF or QRS values should be used to 
determine the participa nt’s eligibility . Computer -interpreted ECGs should be 
overread b y a ph ysician experienced in reading ECGs before excluding participants.
18. Participants with ANY of the following abnormalities in clinical laboratory  tests at 
screening , as assessed b y the stud y-specific laboratory  and confirmed b y a single 
repeat test if deemed necessary :
AST or ALT level ≥1.5 times ULN; 

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 34Total bilirubin level ≥1.5 times the UL N; participants with a history  of Gilbert’s 
syndrome may  have direct bilirubin measured and would be e ligible for this study  
provided the direct bilirubin level is ≤ UL N;
TSH > ULN;
Fasting C -peptide <0.8 ng/mL ;
Serum calcitonin > ULN;
Amy lase > ULN;
Lipase > ULN;
eGFR <60 mL/min/1.73m2as calculated b y MDRD equation;
FPG >270 mg/dL at screening or admission .
Other Exclusions:
19.History  of alcohol abuse or binge drinking and/or any  illicit drug use or dependence 
within 6 months of Screening.
Note: Binge drinking is defined as a pattern of 5 (male) and 4 (female) or more 
alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 
14units per week (1 unit = 8 ounces ([240 mL ] beer, 1 ounce [30 mL] of 40% spirit 
or 3 ounces [90 mL ] of wine).
20.Blood donation (excluding plasma donations) of approximately  1pint (500 mL) or 
more wit hin 60 days prior to dosing. 
21.History  of sensitivity  to heparin or heparin induced thrombocy topenia, if heparin is 
used to flush IV catheters. 
22. Known intolerance to any  GLP -1R agonist.
23.Unwilling or unable to comply  with the criteria in the Lifesty le Considerations
section of this protocol, including restrictions on caffeine, alcohol and tobacco use.
24.Investigator site staff members directl y involved in the conduct of the study and their 
family  members, site staf f members otherwise supervised b y the investigator, or 
Pfizer employ ees, including their family  members, directly  involved in the conduct of 
the study . 
5.3.Lifestyle Considerations
The following guidelines are provided:

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 355.3.1. Meals and Dietary Restrictions
Participants must abstain from all food and drink (except water) at least 8 hours prior 
to the blood sample collection at the outpatient Screening and on- site follow -up 
visits. 
Participants are required to fast for 4 hours (except water) prior to admission to CRU.
Participants must abstain from all food and drink (except water) at least 8 hours prior 
to the first blood sample on inpatient study  days [eg, for FSBG, safet y laboratory , PK, 
or PD assessment].
Noncaffeinated drinks (except as indicated below) may be consumed with meals and 
the evening snack. 
Participants will refrain from consuming red wine, grapefruit, or 
grapefruit -related citrus fruits (eg, Seville oranges, pomelos, grape fruit juices) 
from 7 days prior to the first dose of investigational p roduct until collection of the 
final PK blood sample.
The initial caloric intake/menu assigned to each participant will be based on the 
Harris Benedict formula (sedentary  lifesty le; to be provided to the site prior to study  
start) using the participant’s b ody weight measured at screening. 
Breakfast will be provided at approximately  0800 hours on each inpatient day : 
A standard breakfast will be provided for consumption after dosing on all day s 
except those when liquid meal (for MMTT) is administered;
On da ys where liquid meal is administered, in lieu of breakfast, the meal will be 
provided as 16 ounces of Ensure Plus®and will be administered as listed in the 
SoA. The entire Ensure Plus®meal is to be consumed within 10 minutes (See 
Section 8.9.1).
Lunch will be provided approximately 4 hours after dosing (approximately  
1200 hours) and at approxima tely the same time on each inpatient day . On day s 
withliquid meal for breakfast , lunch will be provided after the 4
-hour post -dose blood 
collection samples for the MMTT have been completed.
Dinner will be provided approximately  10 hours after dosing (appro ximately  
1800 hours) and at approximately  the same time on each inpatient day .
An evening snack may be permitted at approximately  2200 hours on non -MMTT 
days. On day s when the MMTT is performed, an evening snack will be provided. 
On day s with MMTT as list ed in the SoA (including the evening prior to MMTT) 
participants will be encouraged to consume all provided food, including the liquid 

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 36meal and all standard meals and snacks provided on these day s. Meals on these 
days will be standardized such that participants receive the same menus for all 
meals on these day s (including the evening prior).
If participants do not consume their entire meal on Day  -1, they  will be instructed 
to consume the same amount of food (±10%) on the other days with MMTT that 
they ate on Day  
-1. 
The start time of all meals (including liquid Ensure Plus™ meal) on these day s 
will be noted in the CRU source documents and should be available to the sponsor 
on request. Participants will be encouraged to eat all standard meals within 
30minutes on day s with liquid meal administration.
Participants will receive the same snack each evening prior to the MMTT the 
following day . On these day s, participants will be encouraged to consume the 
entire evening snack. 
Parti cipants will not be required to consume all provided food during standard 
meals on other study  days. 
When a meal or snack is scheduled at the same time as an ECG, the meal will be 
provided after the ECGs are completed. 
Details on the meals provided to pa rticipants including the menu items, portion sizes, 
and approximate calories with nutritional macronutrient (% carboh ydrate, fat and 
protein) breakdown of the meal will be maintained in source documentation at the 
CRUs. This information will not be collect ed in the case report form; however, it may  
be submitted to the sponsor on request. The approximate percentage of food 
consumed (based on visual inspection by  the site staff) should likewise be recorded in 
CRU source documents. 
5.3.2. Caffeine, Alcohol, and Tobacco
Participants will abstain from alcohol for 24 hours (or as specified above for red 
wine) prior to admission to the CRU and continue abstaining from alcohol until 
collection of the final blood sample at the follow -upvisit. Participants may undergo 
an alcohol breath test or blood alcohol test at the discretion of the investigator.
Caffeine -containing products, up to the equivalent of two 8-ounce cups of coffee per 
day, will be permitted. 
However, participants must abstain from caffeine
-containing produc ts for a 
minimum of 2 hours prior to all vital signs and ECG measurements conducted 
throughout stud y participation (from screening to the final follow -up visit).
On day s when MMTT is conducted, participants may  ingest caffeine -containing 
products (up to the equivalent of two 8- ounce cups of unsweetened black coffee 

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 37per day ). This may  be permitted provided that there are no additional calories 
consumed and there is no anticipated impact to the MMTT data, that is no sugar, 
sweetener, flavorings, milk, cream etc.
Participants may  use tobacco -or nicotine -containing products as permitted by  the 
CRU (eg, during smoking breaks, or in specified locations).
However, smoking may  not be permitted when it would interfere with the timing of 
scheduled stud y procedures or during frequent sampling procedures (eg, MMTT). In 
addition, participants must abstain from use of tobacco -or nicotine -containing 
products:
For a minimum of 2 hours prior to all vital sign and ECG measurements;
For a minimum of 2 hours prior to and fol lowing administration of investigational 
product.
5.3.3. Activity
Participants will abstain from strenuous exercise (eg, heav y lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each blood collection for clinical 
laboratory  tests. Wa lking at a normal pace will be permitted.
In order to standardize the conditions on PK sampling day s, participants will be 
required to refrain from ly ing down (except when required for BP, pulse rate, and 
ECG measurements), eating, and drinking beverages o ther than water during the first 
4hours after dosing.
5.3.4. Contraception 
The investigator or his or her designee, in consultation with the male participant, will confirm 
that the participant has selected an appropriate method of contraception for the individu al 
male participant and his partner(s) from the permitted list of contraception methods 
(seeAppendix 4 ) and will confirm that the participant has been instructed in its consistent and 
correct use. At time poi nts indicated in the SoA,the investigator or designee will inform the 
male participant of the need to use effective contraception consistently  and correctly  and 
document the conversation and the male participant’s affirmation in the participant’s chart 
(participants need to affirm their consistent and correct use of at least 1 of the selected 
methods of contraception). In addition, the investigator or designee will instruct the 
participant to call immediately  if the selected contrace ption method is discontinued or if 
pregnancy  is known or suspected in the participant’s female partner.
Female participants will not require use of contraception as they  cannot be women of 
childbearing potential.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 385.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  randomly  assigned to study  intervention /enrolled in the study . A 
minimal set of screen failure information is required to ensure transparent reporting of screen 
failure participants to meet the CONSORT publishing requirements and to respond to queries 
from regulatory  authorities. Minimal information includes demograph y, screen failure 
details, eligibility  criteria, and any  SAE.
Individuals who do not meet the eligibil ity criteria for participation in this study  (screen 
failure) may  not be rescreened. As an exception, a participant who otherwise qualified for 
this study  but did not enroll due to positive COVID -19 test, due to recent vaccination (see 
Section 5.2 ), or due to exhibiting COVID -19-related sy mptoms or potential exposure, may  be 
rescreened after an appropriate interval, if judged appropriate b y the investigator . In such 
cases, all screening procedures must be repeated and the participant assigned a new 8 -digit 
SSID.
A participant who qualified for this study  but did not enroll for administrative reasons (eg ,
delay s in I P shi pping, cohort filled) may  be re -screened. In such cases, all screening 
procedures must be repeated (if the time between screening and dosing exceeds 28 day s) and 
the participant assigned a new 8
-digit SSI D.
6.STUDY INTERVENTION(S ) AND CONCOMITANT TH ERAPY
Study intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, medical device(s) , or study  procedure(s) intended to be administered to a study  
participant according to the study  protocol.
For the purposes of this protocol, the term investigational product may  be used 
synony mously  with study  intervention.
For the purposes of this protocol, study  intervention refers toPF-07081532 or matching 
placebo.
6.1.Study Intervention(s) Administered
PF-07081532 and matching placebo will be supplied by  Pfizer as tablets. The tablets will be 
supplied to the CRU in bulk along with individual dosing containers for unit dosing.
6.1.1. Administration
On Day 1, participants will receive IP at approximately  0800 hours (plus or minus 2 hours). 
Dosing of IP is planned to occur in the fed state, ie, with breakfast. Details on meals and 
dietary  requirements and activity  restrictions are given in Lifesty le Considerations section of 
the protocol. Investigator site personnel will administer investigational product with 
approximately  240 mL ambient temperature water . Participants will swallow the 
investigational prod uct whole, and will not manipulate or chew the investigational product 
prior to swallowing. 

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 39Blinding will be maintained by  keeping the number of tablets the same for 
PF-07081532 and placebo within a given cohort . 
6.2.Preparation , Handling , Storage , and Accou ntability
1.
The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  intervention sreceived and an y 
discrepancies are reported and resolved before use of the study  intervention. 
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention. All study  
intervention smust be stored in a secure, environmentally controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff. At a 
minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. D ata for nonworking day s must 
indicate the minimum and maximum temperatures since previousl y documented for 
all site storage locations upon return to business.
3.Any excursions from the study  intervention label storage conditions should be 
reported to Pfizer upon discovery  along with an y actions taken. The site should 
activel y pursue options for returning the stud y intervention to the storage conditions 
described in the labeling, as soon as possible. Once an excursion is identified, the 
study  intervention must be quarantined and not used until Pfizer provides permission 
to use the study  intervention. Specific details regarding the definition of an excursion 
and information the site should report for each excursion will be provided to the site 
in the I P manual.
4.Any storage conditions stated in the SRSD will be superseded by  the storage 
conditions stated on the label.
5.Study  interventions should be stored in their original containers.
6.See the IP manual for storage conditions of the study  intervention.
7.The investiga tor, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability, reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records) , such as the 
IPAL or spons or-approved equivalent . All study  intervention s will be accounted for 
using a study  intervention accountabilit y form/record.
8.Further guidance and information for the final disposition of unused study  
interventions are provided in the I P manual. All destruction must be adequately  
documented. If destruction is authorized to take place at the investigator site, the 
investigator must ensure that the materials are destroy ed in compliance with 
applicable environmental regulations, institutional policy , and any  special instructions 
provided b y Pfizer.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 40Upon identification of a product complaint, notify the sponsor w ithin 1 business day  of 
discovery  as described in the I P manual.
6.2.1. Preparation and Dispensing
Study  intervention and placebo will be prepared by  qualified unblinded site personnel 
according to the IP manual. The study  intervention will be administered in a blinded fashion 
to the participant s.
6.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study Intervention
All participants will be assigned to randomized study  intervention using a randomization 
scheme, maintained b y Pfizer (or designated CRO vendor) . Investigators will remain blinded 
to each participant’s assigned stud y intervention throughout the course of t he study .
Unblinded personnel will access randomization scheme to prepare or dispense the 
appropriate stud y treatment. 
The randomization scheme/list will be provided directly and securel y to the site 
pharmacist(s). The unblinded pharmacist(s) will be responsible for the preparation and 
dispensing of all study  intervention and will endeavor to ensure that there are no differences 
in time taken to dispense or visual presentation following randomization and no blinded site 
staff are able to view the admin istration.
In the event of a Qualit y Assurance audit, the auditor(s) will be allowed access to unblinded 
study  intervention records at the site(s) to verify  that randomization/dispensing has been done 
accuratel y.
6.3.2. Breaking the Blind 
The method for breaking the blind in this study  will be manual. A sealed envelope that 
contains the study  intervention assignment(s) for each participant will be provided to the 
investigator. The sealed envelope will be retained by  the investigator (or representative) in a 
secur ed area. In case of an emergency, the investigator has the sole responsibility  for 
determining if unblinding of a participant’s treatment assignment is warranted. Participant 
safet y must always be the first consideration in making such a determination. If the 
investigator decides that unblinding is warranted, the investigator should make every  effort to 
contact the sponsor prior to unblinding a participant’s treatment assignment unless this could 
delay  further manag ement of the participant. If a participant ’s treatment assignment is 
unblinded, the sponsor must be notified within 24 hours after breaking the blind. When the 
blinding code is broken, the reason must be fully  documented and entered on the CRF/DCT.
Once the stud y is complete, all envelopes (sealed and opened) must be inventoried and 
retained until authorization for destruction has been provided.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 416.4. Study Intervention Compliance
Participants will receive study  intervention directly  from the investigator or designee, under 
medical supervision. The date and time of each dose administered in the clinic will be 
recorded in the source documents and recorded in the CRF. The dose of study  intervention 
and study  participant identification will be confirmed at the time of dosing by  a member of 
the study  site sta ff other than the person administering the study  intervention. Study  site 
personnel will examine each participant’s mouth to ensure that the study  intervention was 
ingested.
6.5. Dose Modification
Refer to Section 4.3for details of dos ing scheme , and circumstances under which 
modifications may  be acceptable .
6.6.Continued Access to Study Intervention A fter the E nd of the Study
No intervention will be provided to study  participants at the end of their study  participation.
6.7.Treatment of Overdose
For this study , any  dose of PF -07081532 greater than 2.5 g is projected to result in exposures 
greater than 404255 ng/mL  for C max(ie, 152 ng/mL  unbound) or 5664894 ng∙h/mL for 
AUC 24(ie, 2130 ng∙h/mL unbound) within a 24- hour time period andwill be considered an 
overdose. The exposures above are based on the unbound exposures at the NOAEL in the 
NHP toxicity  study  (see Section 2.2.1.3) after accounting for protein binding in humans.
There is no specific treatment for an overdose .
In the event of an overdose, the investigator/treating ph ysician should:
1.Contact the medical monitor within 24 hours.
2.Closely  monitor the participant for an y AEs/SAEs and laboratory  abnormalities for at 
least 5 half -lives or 28 calendar day s after the overdose of PF-
07081532 (whichever 
is longer).
3.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
4. Overdose is reportable to Pfizer Safety  only when associated with an SAE.
5.Obtain a blood sample for PK anal ysis within 3days from the date of the last dose of 
study  intervention if requested by  the medical monitor (determined on a case -by-case 
basis).
Decisions regarding dose interruptions or modifications will be made by  the investigator in 
consultation with the medical monitor based on the clinical evaluation of the participant.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 426.8.Concomitant Therapy
6.8.1. Permitted Medications
Participants may  be on certain concomitant medications that have been prescribed to treat 
concurrent diseases such as hy perlipidemia and hypertension. Attempts must be made not to 
alter the doses and regimens of the background/concomitant medications after randomization 
and for the duration of participation in this study . Any  changes must be captured in the CRF. 
Where applicable, participants are expected to brin g their suppl y of permitted prescription 
medications prior to confinement to the unit.
Medications, prescription or non -prescription, or herbal supplements not specificall y listed in 
the protocol may  be permitted, but only  after review and approval by  the sponsor
6.8.1.1. Metformin
All participants enrolling with T2DM are required to be taking metformin monotherap y at a 
minimum dose of 500 mg/day . On all study  days while in the CRU, participants will be given 
their morning dose of metformin at the same time as PF -07081532/placebo. 
Sponsor will not provide metformin during the study  and participants are expected to bring 
their current supply  of metformin prior to confinement to the unit. 
For participants taking metformin more frequentl y than once a day , the invest igator will 
determine the appropriate times during the day  to administer those doses. For metformin 
(required) and other permitted concomitant medications, the timing of administration should 
be the same between inpatient day s, and care should be taken to minimize changes to the 
participants stable medication routine. The dose of metformin, where possible, is expected to 
remain the same until completion of study  participation ie, last follow -up visit. 
6.8.1.2. Antihypertensive and Lipid -
Modifying Agents
The use of background antihy pertensive and/or lipid- modify ing agent(s) is permitted, unless 
prohibited as per Prohibited Medications section of the protocol. Doses of such agents must 
be stable for at least 4 weeks prior to screening and are expected to remain the same until 
completion of study  participation (ie, follow -up visit). 
6.8.1.3. Medications for Management of Nausea and Vomiting
Nausea and vomiting have been reported with administration of GL P
-1R agonists. 
Participants experiencing such sy mptoms may  be managed conservativel y with bed rest 
and/or fluid management at the dis cretion of the investigator. If the nausea and vomiting are 
not amenable to conservative management, anti -emetics (eg, prochlorperazine, promethazine, 
ondansetron) may  be administered at the investigator’s discretion with notification to the 
sponsor and entry  in the CRF.
6.8.2. Prohibited Medications
Use of medications, other than metformin, for gl ycemic control is not permitted in this study .

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 436.8.2.1. Medications Not Permitted During theStudy due to Potential Drug- Drug 
Interaction and Other Prohibited, Prior and Concomit ant Medications
SeeAppendix 8 for list of prohibited concomitant medications due to potential drug -drug 
interaction and Appendix 9 for a list of other, prohibited prior and concomitant medications. 
Sites are encouraged to contact the sponsor should there be questions as to whether a 
medication is permitted or prohibited.
6.8.3. Rescue Medicine
There is no rescue therapy to reverse AEs observed with PF -07081532; standard m edical 
supportive care must be provided to manage any  AEs (see Section 6.8.1.3).
For medical management of hy poglycemia, the investigator may  administer oral 
carboh ydrate, glucagon, or IV glucose according to his or her medical judgment. At a 
minimum however, treatment or administration of a scheduled meal should be given if 
glucose falls 
<60mg/dL for at least 15 minutes, irrespective of whether the participant 
exhibits sy mptoms. I nvestigators may  choose to administer treatment sooner if participants 
have bothersome s ymptoms of hy poglycemia along with glucose values of ≤70mg/dL.
No rescue therap y will be provided for hy pergl ycemia. If a participant has sustained elevated 
fasting plasma glucose concentrations that are >270 mg/dL on 3 consecutive measurements 
over 3 days, that participant will be discontinued, and the investigator will recom mend 
further appropriate gl ycemic treatment according to the local healthcare standards and 
national guidelines.
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
It may  be necessary  for a participant to permanently  discontinue study  intervention .Reasons 
for permanent discontinuation of study  intervention include the following: ECG changes, 
adverse events, laboratory  abnormalities, potential cases of acute kidney  injury  or taking of 
prohibited medications, as described below. 
Note that discontinuation of study  intervention does not represent withdrawal from the stud y.
If study intervention is permanentl ydiscontinued, the participant will remain in the study  to 
be evaluated for safet y and PK, if possible .See the SoA for data to be collected at the time of 
discontinuation of study  intervention and follow -up for any  further evaluations that need to 
be completed.
In the event of discontinuation of study  intervention, it must be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further 
receipt of stud y intervent ion or also from study  procedures, posttreatment study  follow -up, 
and/or future collection of additional information.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 447.1.1. ECG Changes
A participant who meets either bulleted criterion based on the average of triplicate ECG 
readings will be withdrawn from the study intervention . 
QTcF >500 ms ec.
Change from baseline: QTc F>60 msecand QTcF > 450 msec .
If a clinically  significant finding is identified (including, but not limited to ,changes from 
baseline in QT cFafter enrollment ), the investigator or qualified d esignee will determine if 
the participant can continue in the study  and if any change in participant management is 
needed. This review of the ECG printed at the time of collection must be documented. Any 
new clinicall y relevant finding should be reported a s an AE.
7.1.2. Adverse Events
Treatment will be discontinued and the participant withdrawn from the study for:
Treatment -related SAEs;
Other serious or severe AEs, at the discretion of the investigator or sponsor.
7.1.3. Laboratory Abnormalities
All of the following laboratory  abnormalities require discontinuation if they  are confirmed:
Hypergl ycemia: see Section 6.8.3 and Section 8.2.4.2;
Creatine kinase >10 ×ULN;
Note: Urine m yoglobin and SCr will be performed as reflex testing for an y participa nt 
with creatine kinase >10 ×ULN.
AST or ALT that meets ANY of the following:
>3 ×ULN with at least one total bilirubin value >2 ×ULN;
>3 ×ULN accompanied by  signs or s ymptoms consistent with hepatic injury  
(eg,new onset elevated PT/I NR)
;
Two sequential AST or AL T elevations >5 × ULN, regardless of total bilirubin or 
accompan ying signs or sy mptoms.
NOTE: See also Appendix 6 for potential cases of drug -induced liver injury.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 457.1.4. Potential Cases of Acute Kidne y Injury
Abnormal values in SCr concurrent with presence or absence of increase in BUN that meet 
the criteria below, in the absence of other causes of kidney  injury , are considered potential 
cases of acute kidney  injury  and should be considered important m edical events. 
An increase of ≥0.3 mg/dL (or ≥26.5 mol/L) in SCr level relative to the participant’s own 
baseline measurement should trigger another assessment of SCr as soon as practicall y 
feasible, preferabl y within 48 hours from awareness.
If the second assessment (after the first observations of ≥0.3 mg/dL [or ≥26.5 mol/L ] in SCr
relative to the participant’s own baseline measurement) is ≥0.4 mg/dL (or ≥35.4 mol/L ), the 
participant should be discontinued from the stud y and adequate, immediate, supportive 
measures taken to correct apparent acute kidney  injury .
Participants should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the second assessment confirming abnormal 
SCr result. This evaluation should include laboratory  tests, detailed history , and phy sical 
assessment. In addition to repeating SCr, laboratory tests should include serum BUN, serum 
creatine kinase, and serum electrol ytes (including at a minimum potassium, sodium, 
phosphate/phosphorus, and calcium), in addition to urinary  dipstick, urine microscopic 
examination, and urinary indices. All cases confirmed on repeat testing as meeting the 
laboratory  criteria for acute kidney  injury , with no other cause(s) of laboratory  abnormalities 
identified, should be considered potential cases of drug
-induced kidney  injury  irrespective of 
availability  of all the results of the investigations performed to determine etiology  of the 
abnormal SCr. If ≥2healthy  participants at a given dose level are noted to have 2 consecutive
SCr results of ≥0.3 mg/dL (or ≥26.5 mol/L), an assessment of whether the finding may  be 
considered an adverse drug reaction should be undertaken.
7.1.5. Prohibited Medications
Participants who are treated with an y prohibited medication during the course of the study  
may require discontinuation. Participants who are administered or take a prohibited 
medication should be discussed with the sponsor for possible withdrawal from the study .
7.2.Participant Discontinuation/ Withdrawal Fr om the Study
A participant may  withdraw from the study  at an y time at his/her own request. Participants 
may be withdrawn at the discretion of the investigator . Reasons for discontinuation from the 
study  may include the following: safety , behavioral , compliance or administrative reasons , or 
if the study is terminated by  sponsor . 
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted. See the SoA for assessments to be collec ted at the time of study  
discontinuation and follow- up and for an y further evaluations that need to be completed. 

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 46The early  discontinuation visit applies only  to participants who are enrolled/ randomized and 
then are prematurely  withdrawn from the study .Participants should be questioned regarding 
their reason for withdrawal.
If a participant withdraws from the study , he/she may  request destruction of any  remaining 
samples taken and not tested
,andthe investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the participant withdraws from the study  and also withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations should be performed and no 
additional data should be collected. The sponsor may  retain and continue to use any  data 
collected before such withdrawal of consent.
7.2.1. Withdrawal of Consent 
Participant s who request to discontinue receipt of study  intervention will remain in the study  
and must continue to be followed for protocol -specified follow -
up procedures. The onl y 
exception to this is when a participant specificall y withdraws consent for any further contact 
with him or her or persons previously  authorized by  the participant to provide this 
information. Participant s should notify  the investigator in writing of the decision to withdraw 
consent from future follow -up, w henever possible. The withdrawal of consent should be 
explained in detail in the medical records b y the investigator, as to whether the withdrawal is 
only from further receipt of study  intervention or also from study  procedures and/or 
posttreatment study  follow -up, and entered on the appropriate CRF page. In the event that 
vital status (whether the participant is alive or dead) is being measured, publicly  available 
information should be used to determine vital status only  as appropriatel y directed in 
accord ance with local law.
7.3.Lost to Fol low-Up 
A participant will be considered lost to follow- up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contacted b y the study  site.
The following actions must be taken if a participant fa ils to return to the clinic for a required 
study  visit:
The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible . Counsel the participant on the importance of maintaining the 
assigned visit schedule, and ascertain whether the participant wishes to and/or should 
continue in the study ;
Before a participant is deemed lost to follow-up, the investigator or designee must 
make every  effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact attempts should be documented 
in the participant’s medical record ;

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 47Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing any  study -specific procedures.
Study  procedures and their timing are summarized in the SoA .Protocol waivers or 
exemptions are not allowed.
Safety  issues should be discussed with the sponsor immediately  upon occurrence or 
awareness to determine whether the participant should continue or discontinue study  
intervention.
Adherence to the stud
y design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be comp leted and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as ap plicable.
Participants will be screened within 28 days prior to administration of the study  intervention 
to confirm that they  meet the study  population criteria for the study . If the time between 
screening and dosing exceeds 28 days as a result of unexpected delay s (eg, delay ed drug 
shipment), then participants do not require rescreening if the laboratory  results obtained prior 
to first dose administration meet eligibility  criteria.
A participant who qualified for this protocol but did not enroll fr om an earlier cohort/group 
may be used in a subsequent cohort/group without rescreening, provided laboratory  results 
obtained prior to the first dose administration meet eligibility  criteria for this study . In 
addition, other clinical assessments or specim en collections, eg, banked biospecimens, may  
be used without repeat collection, as appropriate.
Procedures conducted as part of the participant’s routine clinical management (eg, laboratory  
data) and obtained before signing of the IC Dmay be utilized for screening or baseline 
purposes provided the procedures met the protocol specified criteria and were performed 
within the time frame defined in the SoA.
Every  effort should be made to ensure that protocol -required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may  be 
circumstances outside the control of the investigator that may  make it unfeasible to perform 
the test. I n these cases, the investigator must take all steps necessary to ensure the safet y and 
well-being of the participant. When a protocol -required test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 48actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible. The study  team must be informed of these incidents in a timely  manner.
All efforts will be made to conduct procedures at the exact nominal time relative to dosing. 
Procedures up to and including 10
hours after dose administration that are conducted within 
10%
of the nominal time (eg, within 6 minutes of a 60 -minute sample) relative to dosing will 
not be captured as a protocol deviation, as long as the exact time of the procedure is noted on 
the source document and data collection tool (eg, CRF /DCT ).Procedures scheduled more 
than 10 hours after dose administration that are conducted ≤1 hour away  from the nominal 
time relative to dosing will not be captured as a protocol deviation, as long as the exact ti me 
of the procedure is noted on the source document and data collection tool (eg, CRF/DCT). 
When multiple procedures are scheduled at the same time point(s) relative to dosing, the 
following chronology  of events should be adhered to, where possible :
ECGs: obtain prior to vital sign measurements and as close as possible to the 
scheduled time, but prior to blood specimen collection ( seeSection 8.2.3 );
Vital Signs (BP and pulse rate): obtain as close as possible to the scheduled time, but 
prior to blood specimen collection ( seeSection 8.2.2 );
Weight: obtain as close as possible to the scheduled time, but prior to eating and 
drinking and prior to dose administration, where applicable (seeSection 8.9.3 ); 
Fasting blood samples: after assessment of 12
-lead ECG and vital signs but prior to 
dosing;
PK blood specimens: obtain at the scheduled time (for 0H samples, c ollect before 
dosing and as close as possible to dosing time, where applicable);
Dosing: must occur at the scheduled nominal time and following predose blood 
sample collection;
Breakfast: provided for consumption following dosing, where applicable (see
Section 5.3.1).
Safety /laboratory /anal yte results obtained following 1stdose of the stud y intervention (Day  1) 
that could unblind the study  (ie,glucose, insulin, glucagon, C
-peptide, HbA1c, and PK), will 
not be reported to investigative sites or other blinded personnel until the study  has been 
unblinded.
If an IV catheter is utilized for blood sample collections, ECGs and vital sign assessments 
(pulse rate and BP) should be collected prior to the insertion of the catheter.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instruct ions and contact information will be provided to the investigator site prior 
to initiation of the study .

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 49The total blood sampling volume for individual participants is approximately , up to 425 mL . 
If participants with obesity  are enrolled, approximately , up to245mL blood will be 
collected
. The actual collection times of blood sampling may  change. Additional blood 
samples may  be taken for safet y assessments at times specified b y Pfizer, provided the total 
volume taken during the study  does not exceed 550 mL during an y period of 56 consecutive 
days.
8.1.Efficacy Assessments
Notapplicable.
8.2.Safety Assessments
Planned time points for all safety  assessments are provided in the SoA.Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  issues.
8.2.1. Physical Examinations
A complete ph ysical examination will include, at a minimum, head, ears, ey es, nose, mouth, 
skin, heart and lung examinations, ly mph nodes, and gastrointestinal, musculoskeletal, and 
neurological s ystems. 
A brief ph ysical examination will include, at a min imum, assessments of general appearance, 
the respiratory  and cardiovascular s ystems, and participant- reported s ymptoms. 
Physical examinations may  be conducted by  a ph ysician, trained ph ysician's assistant, or 
nurse practitioner as acceptable according to local regulation. 
Height will also be measured and recorded per the 
SoA. 
Physical examination findings collected during the study  will be considered source data and 
will not be required to be reported , unless otherwise noted. Any  untoward phy sical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE (Appendix 3 ) must be reported according to the processes in 
Sections 8.3.1 to 8.3.3.
8.2.2. Vital Signs
Supine BP will be measured with the participant’s arm supported at the level of the heart, and 
recorded to the nearest mm Hg after approximately 5 minutes of rest. The same arm 
(preferabl y the dominant arm) will be used throughout the study . Participants should be 
instructed not to speak during measurements. When triplicate measurements are obt ained, 
they should be collected approximately  2minutes apart; the average of the triplicate 
measurements at each nominal time point on Day  
-1 will serve as each participant’s time -
controlled baseline value.
The same properl y sized and calibrated BP cuff w ill be used to measure BP each time. The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 50done manuall y, pulse rate will be measured in the brachial/radial artery for at least 
30seconds. When the timing of these meas urements coincides with a blood collection, BP 
and pulse rate should be obtained prior to the nominal time of the blood collection. 
Additional collection times, or changes to collection times, of BP and pulse rate will be 
permitted, as necessary , to ensur e appropriate collection of safety  data.
8.2.3. Electrocardiograms
Standard 12-lead ECGs utilizing limb leads (with a 10 second rh ythm strip) should be 
collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically  calculates the heart rate and measures PR, QT, and QTc intervals and QRS 
complex. Alternative lead placement methodology  using torso leads (eg, Mason- Likar) 
should not be used given the potential risk of discrepancies with ECGs acquired using 
standard limb lead placement. All scheduled ECGs should be performed after the participant 
has rested quietl y for at least 5 minutes in a supine position. When a meal or snack is 
scheduled at the same time as an ECG, the ECG measurement must be perfo rmed prior to the 
meal/snack.
Triplicate 12 -lead ECGs will be obtained approximately  3minutes (±1 minute) apart; the 
average of the triplicate ECG measurements collected at each nominal time point on Day -
1 
will serve as each participant’s time -controlled baseline value. Any clinically significant 
changes from the baseline/Day 1 ECG may  potentially  be AEs ( Appendix 7) and should be 
evaluated further, as clinically  warranted. 
To ensure safet y of the participants, a qualified 
individual at the investigator site will make comparisons to baseline measurements. 
Additional ECG monitoring will occur if a) the mean value from the triplicate measurements 
for an y postdose QTcF interval is increased b y ≥60msec from the baseline and is 
>450 msec; or b) an absolute QT value is ≥500 msec for an y scheduled ECG. If either of 
these conditions occurs, then a single ECG measurement must be repeated at least hourly 
until QTc values from 2 successive ECGs fall below the threshold value that triggered the 
repeat measurement.
If a) a postdose QTcF interval remains ≥60msec from the baseline andis >450 msec; or b) 
an absolute QT value is ≥500 msec for an y scheduled ECG for greater than 4 hours (or 
sooner, at the discretion of the investigator) ; or c) QTcF intervals get progressively  longer, 
the participant should undergo continuous ECG monitoring. A cardiologist should be 
consulted if QTcF intervals do not return to less than the criteria listed above after 8 hours of 
monitoring (or sooner, at the discretion of the investigator). 
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads be placed in the 
same positions each time in order to achieve precise ECG recordings. If a machine- read QTc 
value is prolonged, as defined above, repeat measurements may  not be necessary  if a 
qualified medical provider’s interpretation determines that the QTcF values are in the 
acceptable range.
ECG values of potential clinical concern arelisted in Appendix 7.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 518.2.4. Clinical Safety Laboratory Assessments
See Appendix 2 for the list of clinical safet y laboratory  tests to be performed and the SoA for 
the timing and frequency. All protocol -required laboratory  assessments, as defined in 
Appendix 2 , must be conducted in accordance with the la boratory  manual and the SoA.
Unscheduled clinical laboratory  measurements may  be obtained at any  time during the study  
to assess an y perceived safet y issues
.
The investigator must review the laboratory  report, document this review, and record any  
clinically  relevant changes occurring during the study  in the AE section of the CRF. 
Clinically  significant abnormal laboratory  findings are those which are not associ ated with 
the underl ying disease, unless judged by  the investigator to be more severe than expected for 
the participant's condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within 3daysafter the last dose of study  intervention should be 
repeated until the values return to normal or baseline or are no longer considered clinically  
significant b y the investigator or medical monitor.
If such values do not return to normal/baseline with in a period of time judged reasonable b y 
the investigator, the etiology  should be identified and the sponsor notified.
See Appendix 6 for suggested actions and follow -up assessments in the event of potential 
drug-induc ed liver injury.
Participants may  undergo random urine drug testing at the discretion of the investigator. 
Drug testing conducted prior to dosing must be negative for participants to receive study 
intervention (exception may  be made for medically  prescribe d benzodiazepines, se e
Section 5.2).
Any remaining serum/plasma from samples collected for clinical safet y laboratory
 
measurements at baseline and at all times after dose administration may  be retained and 
stored for the duration of the study . Upon completion of the study , these retained safety  
samples may  be used for the assessment of exploratory  safet y biomarkers, unexpected safet y 
findings or other internal exploratory  purposes. These data will not be included in the CSR. 
Samples to be used for this purpose will be shipped to either a Pfizer -approved BBS facility  
or other designated laboratory  and retained for up to 1 y ear following t he completion of the 
study .
8.2.4.1. Fasting Fingerstick Blood Glucose (via Glucometer)
Investigators will monitor FSBG using a glucometer at the times specified in the SoA. While 
the participant is confined to the CRU, FSBG measurements should be taken each morning 
before breakfast.
FSBG readings will be maintained at the CRU in source documents, and only  the glucose 
results from the laboratory  will be reported in the study  database. The sites may  share the 
FSBG readings with the sponsor ,if necessary for the purpose of safet y monitoring , but these 

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 52data will be stored in the CRU source documents unless related to an AE as described in 
Section 8.2.4.2 .
If an FSBG result is 
<70 mg/dL
a second FSBG should be obtained to confirm the glucose value –this is in addition 
to a 
venous sample that will be sent to the clinical laboratory  for confirmation. 
if the value from this second FSBG is also <70 mg/dL, the second value will be 
recorded as a h ypoglycemic AE (see Section 8.2.4.2 ). 
FSBG will continue to be monitored until the glucose value returns to ≥
70mg/dL. 
Samples may  be taken more frequentl y if deemed necessary  by the investigator.
FSBG readings from a glucometer are permitted at any  time if the investigator or pa rticipant 
notes sy mptoms of hy poglycemia.
8.2.4.2. Hypoglycemia Reporting
Hypoglycemia will be assessed and reported in several categories: severe hypogl ycemia, 
documented s ymptomatic hy poglycemia, as ymptomatic hy poglycemia, and probable 
hypoglycemia.
Severe hypogl ycemia : In order to be considered severe h ypogl ycemia all of the following 
3criteria must be met:
1.The participant had 1 of the following:
Blood glucose <50 mg/dL; or
If blood glucose was not measured, the clinical manifestations were reversed by  
carboh ydrate administration.
2.The participant required the assistance of another person to activel y administer 
carboh ydrate, glucagon, or other resuscitative actions.
3.The participant exhibited at least 1 of the following neurological s ymptoms:
Memory  loss;
Uncontrollable behavior;
Irrational behavior;
Unusual difficulty  in awakening;
Suspected seizure;
Seizure;

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 53Loss of consciousness.
Documented symptomatic hypoglycemia: An event during which ty pical sy mptoms of 
hypoglycemia are accompanied by  a measured glucose concentration < 70 mg/dL.
Asymptomatic hypoglycemia: An event not accompanied by  typical symptoms of 
hypoglycemia but with a measured glucose concentration <70 mg /dL.
Probable symptomatic hypoglycemia : An event, during which ty pical symptoms of 
hypoglycemia are not accompanied b y a real time glucose determination, but were 
presumabl y caused b y a plasma glucose concentration <70 mg/dL. The clinical picture must 
include prompt resolution with oral carboh ydrates, subcutaneous glucagon, or intravenous 
glucose.
8.3.Adverse Events ,Serious Adverse Events , and Other Safety Reporting
The definitions of an AE and an SAE can be found in A ppendix 3 .
AEs may  arise from s ymptoms or other complaints reported to the investigator by  the 
participant (or, when appropriate, b y a caregiver, surrogate, or the participant's legall y 
authorized representative), or they  may  arise from clinical findings o f the Investigator or 
other healthcare providers (clinical signs, test results, etc.).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
the 
study  intervention (see Section 7.1). 
During the active collection period as described in Section 8.3.1, e ach participant /parent/legal 
guardian/legall y authorized representative will be questioned about the occurrence of AEs in 
a nonleading manner.
In addition, the investigator may  be requested by  Pfizer Safet y to obtain specific follow - up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each partici pant begins from the time the participant provides informed consent, 
which is obtained before the participant ’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving study  intervention ), through and including a 
minimum of 28 calendar days after the last administration of the study  intervention .
Follow -up by  the investigator continues throughout and after the active collection period and 
until the AE or SAE or its sequelae resolve or stabilize at a level acceptable to the 
investigator.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 54For participants who are screen failures, the active collection period ends when screen failure 
status is determined.
If the participant withdraws from the study  and also with draws consent for the collection of 
future information, the active collection period ends when consent is withdrawn.
If a participant permanently discontinues or temporaril y discontinues study intervention 
because of an AE or SAE, the AE or SAE must be rec orded on the CRF and the SAE 
reported using the CT SAE Report Form.
Investigators are not obligated to activel y seek information on AEsor SAE safter the 
participant has concluded study  participation .However, if the investigator learns of an y SAE, 
including a death, at an y time after a participant has completed the study , and he/she 
considers the event to be reasonabl y related to the study  intervention, the investigator must 
promptly  report the SAE to Pfizer using the CT SAE Report Form .
8.3.1.1.
Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.3.1 are reported to Pfizer Safety  on the CT SAE Report Form immediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any  updated SAE data to the sponsor within 
24 hours of it being available.
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection peri od, 
which 
begins after obtaining informed consent as described in Section 8.3.1 , will be recorded 
on the AE section of the CRF.
The investigator is to record on the CRF all directly  observed and all spontaneously  reported 
AEs and SAEs reported by  the participant.
Reporting of AEs and SAEs for participants who fail screening are subject to the CRF 
requirements as described in Section 5.4.
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE sand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 .
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of t
he participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -Up of AEs and SAEs
After the initial AE or SAE report, the investigator is required to proactively  follow each 
participant at subsequent visits/contacts. For each event, the inv estigator must pursue and 

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 55obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination o f 
possible causality . Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary  of available 
autopsy  findings must be submitted as soon as possible to Pfizer Safety . 
Further information on follow -up procedures is given in Appendix 3 .
8.3.4. Regulatory Reporting Requirements for SAEs
Prompt notification by  the investigator to the sponsor of a n SAE is essential so that legal 
obligati ons and ethical responsibilities toward the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agenci es about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs, and investigators.
Investigator safety  repor ts must be prepared for SUSAR saccording to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives SUSAR sor other specific safety information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD (s) for the 
study and will notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and 
Occupational Exposure
Environmental exposure, occurs when a person not enrolled in the study  as a participant 
receives unplanned direct contact with or exposure to the study  intervention. Such exposure 
may or ma y not lead to the occurrence of an AE or SAE. Persons at risk for environmental 
exposure include healthcare providers, famil y members, and others who may be exposed . An 
environmental exp osure may include exposure during pregnancy , exposure during 
breastfeeding ,and occupational exposure .
Any such exposure to the study  interventio nunder study  are reportable to Pfizer Safet y 
within 24 hours of investigator awareness.
8.3.5.1. Exposure During Pregnancy
An EDP occurs if: 
A female participant is found to be pr egnant while receiving or after discontinuing 
study  intervention .

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 56A male participant who is receiving or has discontinued study  intervention exposes a 
female partner prior to or around the time of conception .
A female is found to be pregnant while being e xposed or having been exposed to 
study  intervention due to environmental exposure. Below are examples of 
environmental EDP :
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention byingestion . 
A male famil y member or healthcare provider who has been exposed to the study  
intervention by ingestion then exposes his female partner prior to or around the 
time of conception .
The investigator must report EDP to Pfizer Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below for information rel ated to 
termination of pregnancy). 
If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to Pfizer Safety on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details of the 
pregnancy  will be collected after the start of study  intervention and until at least 5 
terminal half -lives after the last dose.
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to Pfizer Safety  using the CT SAE Report Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study , the information is not recorded on a CRF; however, a copy  of the 
completed CT SAE Report Form is maintained in the investigator site file.
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP S upplemental Form. In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by gross visual inspect ion (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are considered SAEs. If the outcome of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y in a live -born bab y, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 57for reporting SAEs. Additional information about pregnancy  outcomes that are reported to 
Pfizer Safety  as SAEs follows: 
Spontaneous abortion includ ingmiscarriage and missed abortion;
Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality , as SAEs. Inaddition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the study  intervention. 
Additional information regarding the EDP may  be requested by  the sponso
r. Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
8.3.5.2. Exposure During Breastfeeding
An exposure during breastfeeding occurs if: 
A female participant is found to be breastfeeding while receiving or after 
discontinuing study  intervention .
A female is found to be breastfeeding while being exposed or having been exposed to 
study  intervention (ie, env ironmental exposure). An example of environmental 
exposure during breastfeeding is a female family  member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the study  intervention
byingestion .
The investigator must report exposure during breastfeeding to Pfizer Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred. The 
information must be reported using the CT SAE Report Form. When exposure during 
breastfeeding occurs in the setting of environmental exposure, the exposure information does 
not pertain to the participant enrolled in the study , so the information is not recorded on a 
CRF. However, a cop y of the completed CT SAE Report Form is maintained in the 
investigator si te file.
An exposure during breastfeeding report is not created when a Pfizer drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use. However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.
8.3.5.3. Occupational Exposure
The investigator must report any  instance of occupational exposure to Pfizer Safet y within 
24
hours of the investigator’s awareness using the CT SAE Report Form , regardless of 

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 58whether there is an associated SAE. Since the information about the occupational exposure
does not pertain to a participant enrolled in the study , the information is not recorded on a 
CRF; however, a cop y of the completed CT SAE Report Form must be maintained in the 
investigator site file .
8.3.6. Cardiovascular and Death Events
Not applicable .
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable .
8.3.8. Adverse Events of Special Interest
Not applicable .
8.3.8.1. Lack of Efficacy
This section is not applicable because efficacy  is not expected in the study  population.
8.3.9. Medical Device Deficiencies
Not applicable .
8.3.10. Medication Errors
Medication errors may  result from the administration or consumption of the 
study  
intervention by the wrong participant , or at the wrong time, or at the wrong dosage strength.
Exposures to the study  intervention under stud y may occur in clinical trial settings, such as 
medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form to Pfizer Safety Within 
24 Hours of Awareness
Medication errors All (regardless of whether 
associated with a n AE)Only  if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention ;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant .
Such medication errors occurring to a stud
y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 59In the event of a medication dosing error, the sponsor should be notified within 24 hours.
Whether or not the medication error is accompanied by  an AE, as determined by  the 
investigator, the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are rec orded on 
theAE page of the 
CRF. 
Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report 
Form only when associated with an SAE.
8.4.Pharmacokinetics 
8.4.1. Plasma for Analysis of PF -07081532
Blood samples of approximately  3mL, to p rovide approximately  1mL of plasma, will be 
collected into appropriately  labeled tubes containing K2EDTA for measurement of plasma 
concentrations of PF- 07081532 at times specified in the SoA. Instructions for the collection 
and handling of biological samples will be provided in the laboratory  manual or by  the 
sponsor. The actual date and time (24 -hour clock time) of each sample will be recorded.
The actual times may  change, but the number of samples will remain the same. Any  chan ges 
in the timing or addition of time points for an y planned study assessments must be 
documented and approved by  the relevant study  team member and then archived in the 
sponsor and site study  files but will not constitute a protocol deviation .
Samples wil l be used to evaluate the PK of PF -07081532. Samples collected for 
measurement of plasma concentrations of PF -07081532 will be anal yzed using a validated 
analytical method in compliance with applicable SOPs.
Samples collected for analy ses of PF -07081532 pl asma concentrations may  also be used to 
evaluate safet y or efficacy aspects related to concerns arising during or after the study, for 
metabolite identification and/or evaluation of the bioanaly tical method, or for other internal 
exploratory  purposes. Gene tic anal yses will not be performed on these plasma samples 
(unless consent for this was included in the informed consent). Participant confidentiality  
will be maintained. An y remaining volume may  be retained and stored for the duration of the 
study . Upon c ompletion of the study , these retained samples may be used for exploratory  
purposes. An y such data generated will not be included in the CSR. Samples to be used for 
this purpose will be shipped to either a Pfizer -approved BBS facility  or other designated 
laboratory  and retained for up to 1 year following the completion of the study .
The PK samples must be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity . Any  deviations from the PK sample 
handling procedure (eg, sample collection and processing steps, interim storage or shipping 
conditions), including any actions taken, must be documented and reported to the sponsor. 
On a case -by-case basis, the sponsor may  decide as to whether sample integr ity has been 
compromised.

PF-07081532
Protocol C3991003Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 60Drug concentration information that may unblind the study will not be reported to 
investigator sites or blinded personnel until the study has been unblinded.
8.4.2. Plasma for Analysis of 4- β-hydroxycholesterol/cholesterol
Blood samples of approximately 4 mL, to provide plasma volume of approximately 2 mL, 
will be collected into appropriately labeled tubes containing lithium heparin at times specified in the SoA. As part of the understanding of the properties of the investigational 
product, these samples may be used for analysis of 4- β-hydroxycholesterol/cholesterol as a 
marker of CYP3A activity, for metabolite identification, evaluation of bioanalytical methods and/or other internal exploratory purposes. Data generated from these samples may not be included in the CSR. Instructions for the collection and handling of biological samples will be provided in the laboratory manual. 
 
 
 
 
 
 
 
 
 
 CCI
CCI
PF-07081532
Protocol C3991003Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 61 
 
8.7. Immunogenicity Assessments
Immunogenicity assessments are not included in this study.
8.8. Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study.
8.9. Pharmacodynamics
Samples will be analyzed using a validated analytical method in compliance with 
Pfizer/vendor SOPs.
The PD samples must be processed and shipped (if needed) as indicated in the instructions 
provided to the investigator site to maintain sample integrity. Any deviations from the PD sample handling procedure (eg, sample collection and processing steps, interim storage or shipping conditions), including any actions taken, must be documented and reported to the sponsor. On a case-by-case basis, the sponsor may make a determination as to whethersample integrity has been compromised. Any deviation from the specified sample handling procedure resulting in compromised sample integrity will be considered a protocol deviation.
As part of understanding the PD effects of PF-07081532, samples may be used for evaluation 
of the bioanalytical method, as well as for other internal exploratory purposes. Any remaining volume may be retained and stored for the duration of the study. Upon completion of the study, these retained samples may be used for exploratory purposes. Any such data generated will not be included in the CSR. Samples to be used for this purpose will be shipped to either a Pfizer-approved BBS facility or other designated laboratory and retained for up to 1 year following the completion of the study.
8.9.1. Liquid Meal (for MMTT)
A liquid meal consisting of approximately 700 kcal ( 16 fluid ounces ) of Ensure Plus
®
(Vanilla) will be administered to the participants as listed in the SoA. The liquid meal will be 
consumed within approximately 10 minutes on all MMTT days. 
8.9.2. Plasma Glucose, Plasma Insulin, C-Peptide, Glucagon and HbA1c 
At each timepoint specified in the SoA, a sufficient amount of blood will be collected for 
analysis of plasma glucose, plasma insulin, C-peptide, glucagon, and HbA1c for MMTT. 
The timing of blood samples for assessment of AUC (0-4)as part of the MMTT will be based 
on the start time of the liquid meal such that the sample for the 15-minute time point is collected approximately 5 minutes after completion of the liquid meal.CCI
PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 62Where triplicate FPI is to be measured, the 3 samples should be collected approximately  5 
minutes apart. FPI and FPG values will be used to calculate HOMA -IR (see Section 9.3.4 ). 
8.9.3. Body Weight
Body weight measurements will be obtained at the time points outlined in the SoA. If 
possible, the same scale sho uld be used for a particular participant for all body  weight 
measurements obtained at the CRU. For measuring weight, a scale with appropriate range 
and resolution is used and must be placed on a stable, flat surface. 
Body weight will be measured at outpatient visits to the study  site as listed in the SoA under 
the following conditions:
After void of urine ;
After removal of shoes, bulky  layers of clothing, and jackets so that only  light 
clothing remains; 
While remaining still during measurement. 
During admission to the CRU, body  weight will be measured at the time points listed in the 
SoA. Measurement will be taken under the following conditions:
In the morning, prior to eating and drinking and prior to dose administration, where 
applicable;
After the participant has been asked to void;
While wearing onl y a hospital gown and no shoes;
While remaining still during measurement.
9.STATISTICAL CONSIDER
ATIONS
Detailed methodology  for summary  and statistical anal yses of the data collected in this study  
is outlined here and further detailed in a SAP, which will be maintained b y the sponsor. The 
SAP may  modify  what is outlined in the protocol where appropriate; however, any  major 
modifications of the primary  endpoint def initions or their anal yses will also be ref lected in a 
protocol amendment.
9.1.Statistical Hypotheses
No formal statistical h ypothesis testing will be performed in this study .
9.2.Analysis Sets
For purposes of analy sis, the following anal ysis sets (Table 4) are defined:

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 63Table 4. Populations to be Analyzed
Participant Analysis Set Description
Enrolled /Randomly  
assigned to stud y 
intervention"Enrolled" means a participant's, or their legall y authorized
representative’s, agreement to participate in a clinical study  
following completion of the informed consent process and 
screening . Potential participants who are screened for the 
purpose of deter mining eligibility  for the stud y, but do not 
participate in the stud y, are not considered enrolled, unless 
otherwise specified b y the protocol. A participant will be 
considered enrolled if the informed consent is not withdrawn 
prior to participating in any study  activity  after screening.
Full Anal ysis Set All participants randomly  assign ed to study  intervention and 
who take at least 1dose of study  intervention .
Safety Anal ysis Set All participants randomly  assigned to study  intervention and 
who take at least 1 dose of study  intervention .Participants will 
be anal yzed according to the product they actually  received.
PK Concentration Set The PK concentration population is defined as all randomized 
participants who received at least 1 dose of PF -07081532 and 
in whom at least 1 plasma concentration value is reported.
PK Parameter Set The PK parameter population is defined as all randomized 
participants that received at least 1 dose of PF -07081532 and 
have at least 1 of the PK parameters of interest calculated.
PD population Set The PDpopulation set is defined as all randomized 
participants that received at least 1 dose of PF -07081532 and 
have at least 1 of the PDparameters of interest calculated.
9.3. Statistical Analyses
The SAP will be developed and finalized before any anal yses are pe rformed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data.
This section is a summary of the planned statistical analy ses of the primary  and secondary  
endpoints.
9.3.1. General C onsiderations
9.3.2. Primary Endpoint
All participants who received at least 1 dose of study  intervention will be included in the 
safet y analyses and listings . AEs, ECGs, BP, pulse rate, and safety  laboratory  data will be 
reviewed and summariz ed on an ongoing basis during the stud y to evaluate the safet y of 

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 64participants. An y clinical laboratory, ECG, BP, and pulse rate abnormalities of potential 
clinical concern will be described . Safet y data will be presented in tabular and/or graphical 
format and summarized descriptivel y, where appropriate.
Medical history  and phy sical examination information, as applicable, collected during the 
course of the stud y will be considered source data and will not be required to be reported, 
unless otherwise noted . However, an y untoward findings identified on ph ysical and/or 
neurological examinations conducted during the active collection period will be captured as 
AEs, if those findings meet the definition of an AE . 
Data collected at screening that are used for inc lusion/exclusion criteria, such as laboratory  
data (unless noted below), ECGs, and vital signs, will be considered source data, and will not 
be required to be reported, unless otherwise noted . Demographic data collected at screening 
will be reported . In ad dition, selected screening laboratory  data: free T4, HbA1c, TSH, 
calcitonin, am ylase, lipase, TBA and C -peptide will be reported.
9.3.2.1. Electrocardiogram Analyses
Changes from baseline for the ECG parameters QT interval, heart rate, QTc interval, PR 
interval, an d QRS complex will be summarized by  treatment and time.
The number (%) of participants with maximum postdose QTc values and maximum increases 
from baseline in the following categories will be tabulated b y treatment: 
Safety QTc Assessment
Degree of Prolongation Mild (msec) Moderate (msec) Severe (m sec)
Absolute value >450 -480 >480 -500 >500
Increase from baseline 30-60 >60
At the nominal time points, the mean of the triplicate measurements will be used to represent 
a single observation at that time point . If any of the 3 individual ECG tracings has a QTcF 
value  500 msec, but the mean of the triplicates is not >500 msec, the data from the 
participant’s individual tracing will be described in a safet y section of the study  report in 
order to place the >500 msec value in appropriate clinical context. However, values from 
individual tracings within triplicate measurements that are 500msec will not be included in 
the categorical analy sis unless the average from the triplicate measurements is also 
500msec.
In addition, an attempt may be made to explore and characterize the relationship between 
plasma concentration and QT interval length using a PK/PD modeling approach . The results 
of such anal yses will not be included in the CSR.
9.3.3. Secondary Endpoints
The populations for PK concentration and PK parameter anal yses are defined in Table 4.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 65PK parameters for PF -07081532 following multiple dose administration will be derived from 
the concentration -time profiles using non -compartmental methods as data permit. The PK 
parameters to be assessed in this study , their definition, and method of determination are 
outlined in Table 
5. In all cases, actual PK sampling times will be used in the derivation of 
PK parameters. PK samples from placebo samples will not be routinely  analy zed. 
The plasma PK parameters will be summarized descriptively  by treatment and day . Each 
c
ohort will be considered as a separate treatment. If data permit, dose-normalized area under 
the plasma concentration time profile from time 0 to 24 hours [AUC 24(dn)] an d 
dose-normalized C max[Cmax(dn)] may be plotted against treatment for each day (potentially  
on a logarithmic scale depending on the extent of the dose range), and will include individual 
participant values and the geometric means for each treatment . Thes e plots will be used to 
help understand the relationship between the PK parameters and dose.
Plasma concentrations of PF
-07081532 will be listed and descriptively  summarized by
treatment, day  and nominal PK sampling time . Individual participant and median profiles of 
the plasma concentration -time data will be plotted by  treatment and day using actual and 
nominal times, respectively . Median profiles will be presented on both linear -linear and log -
linear scales. Each cohort will be considered as a separate tr eatment.
Table 5
Definition of Plasma PK Parameters for PF-07081532
Param eter Day 1 (D1) or 
Day 42 (D42)Definition Method of Determ ination
Cmax D1 and D42 Maximum plasma concentration 
observed from time zero to 
24hoursObserved directly from data
Tmax D1 and D42 Time for C max Observed directly from data as time of 
first occurrence
AUC 24 D1 and D42 Area under the plasma 
concentration -time profile from 
time zero to time 24 hoursLinear/Log trapezoidal method
t½aD42 Term inal half -life Log e(2)/k el, where k elis the terminal 
phase rate constant calculated by a 
linear regression of the log -linear 
concentration -time curve. Only those 
data points judged to describe the 
terminal log -linear decline will be 
used in the regression.
Cmax(dn) D1 and D42 Dose norm alized C max Cmax/Dose
AUC 24(dn) D1 and D42 Dose normalized AUC 24 AUC 24/Dose
Cmin D42 Minimum plasma concentration 
during the dosing intervalObserved directly from data
Cav D42 Average concentration over 24 
hoursAUC 24/24
CL/FaD42 Apparent clearance Dose/AUC 24
Vz/FaD42 Apparent volume of distribution Dose/(AUC 24* k el)

PF-07081532
Protocol C3991003Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 66Table 5 Definition of Plasma PK Parameters for PF-07081532
Parameter Day 1 (D1) or 
Day 42 (D42)Definition Method of Determination
PTR D42 Peak-to-trough ratio C max/Cmin
Rac D42 Observed accumulation ratio for 
AUC 24Steady State AUC 24(dn)/Day 1 
AUC 24(dn)
Rac,Cmax D42 Observed accumulation ratio for 
CmaxSteady State C max(dn)/Day 1 C max(dn)
AUC last D42 Area under the plasma 
concentration-time profile from time zero to time of last quantifiable concentrationLinear/Log trapezoidal method
AUC infaD42 Area under the plasma 
concentration-time profile from 
time zero extrapolated to 
infinite timeAUC last+ (C last*/k el),
where C last* is the predicted plasma 
concentration at the last quantifiable 
time point estimated from the log-linear regression analysis and k
elis the 
terminal phase rate constant calculated by a linear regression of the 
log-linear concentration-time curve. 
Only those data points judged to describe the terminal log-linear decline will be used in the regression.
a. If data permitThis table includes all PK parameters; AUC
24, Cmax, Tmax, t½are secondary endpoints, all others are 
explorator y.
9.3.4. Other Analyse(s)
The MDG will be computed by AUC 24/24 hour. 
The AUC (0-4)for glucose, insulin, glucagon and C-peptide will also be calculated. 
HOMA-IR will be mathematically calculated using FPG and FPI values. All exploratory PD endpoints related to glucose, insulin, C-peptide, glucagon, HbA1c, and 
HOMA-IR will be summarized descriptively by treatment, time point and day. Additional analyses or summaries of these endpoints will be detailed in the SAP. Analysis of exploratory endpoints may not be included in the CSR. 
For body weight, absolute values, CFB, and percent CFB will be summarized descriptively 
by treatment and day where the set of summary statistics will include n, mean, median, SD, minimum, and the maximum.
 
 
CCI
PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 67Analy sis of 4-β- hydroxycholesterol/cholesterol levels in plasma samples, if performed, will 
not be report ed in the CSR.
9.4.Interim Analyses
No formal interim anal ysis will be conducted for this study . As this is a sponsor -open
study ,the sponsor may  conduct unblinded reviews of the data during the course of the study  
for the purpose of safet y assessment, facilitating dose selection decisions, facili tating PK/PD 
modeling, and/or support ingclinical development.
9.5.Sample Size Determination
A sufficient number of participants will be screened to achieve an estimated total of 
approximately  12 evaluable participants per cohort (9 PF -07081532:3 placebo). 
The number of participants was selected empirically  to provide a sufficient number of 
participants to assess and characterize the safet y and tolerability of various doses and dosing  
schemes of PF -07081352.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 6810. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines , including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines ;
Applicable ICH GCP guidelines;
Applicable laws and regulations , including applicable privacy  laws .
The protocol, protocol amendments, I CD, SRSD(s) , and other relevant documents (eg, 
advertisements) must be reviewed and approved by the spon sor,submitted to an I RB/EC by  
the investigator ,and reviewed and approved b y the I RB/EC before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for change s necessary  to eliminate an immediate 
hazard to study  participants.
Protocols and an y substantial amendments to the protocol will require health authority  
approval prior to initiation except for changes necessary
 to eliminate an immediate hazard to 
study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  the IRB/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
IRB/EC procedures
;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the I RB/EC, European regulation 
536/2014 for clinical studies (if applicable), European Medical Device Regulation 
2017/745 for clinical device research (if applicable), 
and all other applicable local 
regulations .
10.1.1.1. Reporting of Safety Issues and Serious Brea ches of the Protocol or ICH GCP
In the event of any  prohibition or restriction imposed (ie, clinical hold) by  an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the study  
intervention , Pfizer should be informed immediately . 

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 69In addition, the investigator will inform Pfizer immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study participants against an y immediate hazard, and 
of an y serious breaches of this protocol or of the ICH GCP guidelines that the investigator 
becomes aware of.
10.1.2. Informed Consent Process
The investigator or his/her representative will explain the nature of the study , including the 
risks and benefits, to the participant or his/her legally  authorized representative and answer 
all questions regarding the study . The participant or his/her legall y authorized representative 
should be given sufficient time and opportunity  to ask questions and to decide wheth er or not 
to participate in the trial.
Participants must be informed that their participation is voluntary . Participants or their 
legally  authorized representative will be required to sign a statement of informed consent that 
meets the requirements of 21 C FR 50, local regulations, I CH guidelines, privacy  and data 
protection requirements, where applicable, and the I RB/EC or study  center.
The investigator must ensure that each study  participant or his or her legally  authorized 
representative is fully  informed about the nature and objectives of the study , the sharing of 
data related to the study ,
and possible risks associated with participation, including the risks 
associated with the processing of the participant ’s personal data. 
The participant or his or her legall y authorized representative must be informed that his/her 
personal stud y-related data will be used by  the sponsor in accordance with local data 
protection law. The level of disclosure must also be explained to the participant or his or her 
legally  authorized representative .
The participant or his or her legall y authorized representative must be informed that his/her 
medical records may  be examined by  Clinical Quality  Assurance auditors or other authorized 
personnel appointed b y the sponsor, b y appropriate I RB/EC members, and by  inspectors 
from regulatory  authorities.
The investigator further must ensure that each study  participant or his or her legall y 
authorized representative is fully informed about his or her right to access and correct his or 
her personal data and to withdraw consent for the processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the partic ipant was enrolled in the study
 and the date on which the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the IC D.
Participants or his or her legally authorized representative must be reconsented to the most 
current version of the IC D(s) during their participation in the study .
A cop y of the IC D(s) must be provided to the participant or the participant’s legall y 
authorized representative.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 70Participants who are rescreened are required to sign a new ICD .
10.1.3. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encr ypted electronic and/or paper 
form and will be password -protected or secured in a locked room to ensure that only  
authorized study  staff have access. The study  site will implement appropriate technical and 
organizational measures to ensure that the persona l data can be recovered in the event of 
disaster. In the event of a potential personal data breach, the study site will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifications as require d by law.
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  this single, participant-specific code. The study  site will 
maintain a confidential list of participant s who participated in the study, linking each 
participant ’s numerical code to his or her actual identity and medical record ID. In case of 
data transfer, the sponsor will protect the confidentiality  of participant s’ personal data 
consistent with the c linical s tudy agreement and applicable privacy  laws.
10.1.3.1. Data Monitoring Committee 
This study  will not use a DMC.
10.1.4. Dissemination of Clinical Study Data
Pfizer fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applicable local 
laws/regulations. In addition, Pfizer reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner and ar e reported regardless of the outcome of the study  or the country  in 
which the study  was conducted.
www.clinicaltrials.gov
Pfizer posts clinical trial results on www.clinicaltrials.gov for Pfizer- sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted. These r esults are 
submitted for posting in accordance with the format and timelines set forth by  US law.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 71EudraCT
Pfizer posts clinical trial r esults on EudraCT for Pfizer -sponsored interventional studies in 
accordance with the format and timelines set forth by  EU requirements.
www.pfizer.com
Pfizer posts public disclosure s ynopses (CSR synopses in which an y data that could be use d 
to identify  individual participants have been removed) on www.pfizer.com for 
Pfizer -sponsored interventional studies at the same time the corresponding study  results are
posted to www.clinicaltrials.gov .
Documents within marketing authorization packages/ submissions
Pfizer complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website. Clinical data, under Phase 1 of this policy , includes clinical 
overviews, clinical summaries, CSRs, and appendices containing the protocol and protocol 
amendments, sample CRFs, and statistical methods. Clinical data, under Phase 2 of this 
policy , includes the publishing of individual participant data. Policy  0070 applies to new 
marketing authorization applications submitted via t he centralized procedure since 
01January 2015 and applications for line extensions and for new indications submitted via 
the centralized procedure since 01 July  2015.
Data sharing
Pfizer provides researchers secure access to patient- level data or full CSR s for the purposes 
of “bona -fide scientific research” that contribute sto the scientific understanding of the 
disease, target, or compound class. Pfizer will make data from these trials available 
24months after study  completion. Patient- level data will be anon ymized in accordance with 
applicable privacy  laws and regulations. CSRs will have personally  identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy ses.Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.5. Data Quality Assurance
All participant dat a relating to the stud y will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  physically or 
electronically  signing the CRF.
Guidance on completion of CRFs will be provided in the CRF Completion Requirements 
document .

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 72The investigator must ensure that the CRFs are securel y stored at the study site in encrypted 
electronic and/or paper form and are password protected or secured in a locked room to 
prevent access b y unauthorized third parties.
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data doc uments. This 
verification may  also occur after study  completion. I t is important that the investigator(s) and 
their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy , including definition of study  critical data items and 
processes (eg, risk- based initiatives in operations and quality  such as risk management and 
mitigation strategies and analytical risk-based m onitoring), methods, responsibilities, and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual , or on- site monitoring) , are provided in the data management plan and 
monitoring plan maintained and utilized by  the sponsor or designee .
The sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.
Records and documents, including signed IC Ds, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor. No records may  be 
transferred to anothe r location or party without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y for aslong as they  are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copies of such 
data are promptly  and irrevocabl y deleted from all systems.
The investigator(s) will notify thesponsor or its agents immediately  of any  regulatory  retain 
notification in relation to the study . Furthermore, the investigator will cooperate 
with the 
sponsor or its agents to prepare the investigator site for the inspection and will allow the 
sponsor or its agent, whenever feasible, to be present during the inspection. The investigator 
site and investigator will promptly  resolve an y discrepanci es that are identified between the 
study  data and the participant's medical records. The investigator will promptly  provide 
copies of the inspection findings to the sponsor or its agent. Before response submission to 
the regulatory  authorities, the investi gator will provide the sponsor or its agents with an 
opportunity  to review and comment on responses to any  such findings.
10.1.6. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data col lected. Source document s are filed at the investigator site.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 73Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained . The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.
In this stud y, the CRF will serve as the source document. A document must be available at 
the investigative site thatidentifies those data that will be r
ecorded on the CRF and for which 
the CRF will be the sourcedocument.
Definition of what constitutes source data and its origin can be found in the investigator site 
file, which is maintained by  the sponsor.
Description of the use of the computerized sy stem is documented in the Data Management 
Plan, which is maintained by  the sponsor.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
Study  monitors will per form ongoing source data verification to confirm that data entered 
into the CRF by  authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP guidelines, and all applicable regulatory  requirements.
10.1.7. Study and Site Start and Closure
The study  start date is the date on which the clinical stud y will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to the sponsor 
or designee/ CRO if requested to do so by  the responsible I RB/EC or if such termination is 
required to protect the health of study  participants .
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or the ICH GCP 
guidelines ;

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 74Inadequate recruitment of participants by  the investigator;
Discontinuation of further study  intervention development .
Study  termination is also provided for in the clinical study  agreement. If there is any  conflict 
between the contract and this proto col,the contract will control as to termination rights.
10.1.8. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1year after the end of the stud y 
(or study  termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any  subsequent publications ,
such as secondary manuscripts, and submit s all manuscripts or abstracts to the sponsor 
30days befo re submission. This allows the sponsor to protect proprietary information and to 
provide comments , and the investigator will, on request, remove an y previously undisclosed 
confidential information before disclosure, except for an y stud y-or Pfizer 
intervention -related information necessary  forthe appropriate scientific presentation or 
understanding of the study  results.
For all publications relating to the stud y, the investigator will compl y with recognized ethical 
standards concerning publications and aut horship, including those established by  the 
International Committee of Medical Journal Editors.
The sponsor will comply  with the requirements for publication of the over all study  results 
covering all i nvestigator sites. In accordance with standard editoria l and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data. In this case, a coordinating investigator will be designated by  mutual 
agreement.
Authorship of publications for the overall study  results will be determined by  mutual 
agreement and in line with I nternational Committee of Medical Journal Editors authorship 
requirements. 
If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.
10.1.9. Sponsor’s Qualified Medical Personnel
The contact information for the sponsor's appropriately qualified medical personnel for the 
study  is documented in the study  contact list located in the study  team on demand (SToD).
To facilitate access to appropriatel y qualified medical personnel for study -related medical 
questions or problems, participants are provided with an Emergency  Contact Card (ECC) at 
the time of informed consent. The ECC contains, at a minimum, (a) protocol and study  
intervention identifiers, (b) participant’s stud y identification number, (c) site emergency 
phone number active 24 hours/day , 7 day s per week, and (d) Pfizer Call C enter number.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 75The ECC is intended to augment, not replace, the establ ished communication pathway s 
between the investigator, site staff, and study  team. The ECC is to be used by  healthcare 
professionals not involved in the research stud y only , as a means of reaching the investigator 
or site staff related to the care of a par ticipant. The Pfizer Call Center number should only  be 
used when the investigator and site staff cannot be reached. The Pfizer Call Center number is 
not intended for use b y the participant directly ; if a participant calls that number directl y, he 
or she wi ll be directed back to the investigator site.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 7610.2. Appendix 2: Clinical Laboratory Tests
The following safet y laboratory  tests will be performed at times defined in the SoA section of 
this protocol. Additional laboratory  results may  be re ported on these samples as a result of 
the method of anal ysis or the ty pe of anal yzer used by  the clinical laboratory ,or as derived 
from calculated values. These additional tests would not require additional collection of 
blood. 
Unscheduled clinical labo ratory  measurements and/or reflex testing may be obtained at an y 
time during the stud y at the discretion of the investigator to assess any  perceived safety  
issues.
Table 6. Protocol -Required Safety Laboratory Assessments
Hem atology Chemistry/Other Urinalysis At specified times 
Hem oglobin
Hem atocrit
RBC count
MCV
MCH
MCHC
Platelet count
WBC count
Total neutrophils (Abs)
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)BUN/Urea 
Serum Creatininea
Plasm aGlucose (fasting)
Calcium
Sodium
Potassium
Chloride
Total CO 2(bicarbonate)
AST
ALT
Total bilirubin
Direct bilirubin
Indirect bilirubin
Alkaline phosphatase
Uric acid
Albumin
Total Bile AcidspH
Glucose (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte esterase
Urobilinogen
Urine bilirubin
MicroscopybAt screening only:
FSHc
HBsAg
HCV Ab
HBcAb
HBsAb
HIV
C-peptided
At times specified in the SoA:
Urine drug screeninge
Free T4
TSH
Calcitonin
Amylase
Lipase
Lipid profile (ie, total 
cholesterol, triglycerides, 
direct HDL, direct LDL)
a. GFR will be calculated using the MDRD equation: GFR (ml/min/1.73m2) = 175 ×standardized Serum Creatinine -
1.154 × age-0.203 ×1.212 [if Black ] × 0.742 [if female].
b. Only if urine dipstick is positive for blood, protein, nitrites, or leukocyte esterase.
c. For confirmation of postmenopausal status in female participants only.
d. C-peptide is collected as part of safety laboratory tests at Screening (collect ed as part of MMTT at other times 
indicated in Table 1and Table 2).
e. The minimum requirement for drug screening includes cocaine, THC, opiates/opioids, benzodiazepines, and 
amphetamines (others are site and study specific).
The investi gator must review the laboratory  report, document this review, and record any  
clinically  relevant changes occurring during the study in the AE section of the CRF.
Safety /laboratory /anal yte results obtained following firstdose of the study  intervention (Day  
1) that could unblind the study  (ie,glucose, insulin, glucagon, C-peptide, HbA1c, and PK), 

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 77will not be reported to investigative sites or other blinded personnel until the study  has been 
unblinded .

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 7810.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -
Up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study 
participant, temporall y associated with the use of study intervention, whether or not 
considered related to the study  intervention.
Note: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
temporally  associated with the use of stud y intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator .Any abnormal laboratory test 
results that meet an y of the conditions below must be recorded as an AE:
Is associated with accompany ing s ymptoms.
Requires additional diagnostic testing or medical/surgical intervention .
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional 
concomitant drug treatment, or oth er therap y.
Exacerbation of a chronic or intermittent preexisting condition, including either an 
increase in frequency  and/or intensity  of the condition.
New condition detected or diagnosed after stud y intervention administration ,even 
though it may  have b een present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE
or SAE unless it is an intentional overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequelae.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 79Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments that are associated with the underl ying disease, unless judged by  the 
investigator to be more severe than expected for the participant’s condition.
The disease/dis order being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads t o the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present 
or detected at the start of the study  that do not worsen.
10.3.2. Definition of an SAE
AnSAE is defined as any untoward medical occurrence that, at any dose, meets one 
or more of the criteria listed below:
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event that
hypothetically  might have caused death if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalization signifies that the participant has been admitted (usually  
involving at least an overnight stay ) at the hospital or emergency  ward for observation 
and/or treatment that would not have been appropriate in the phy sician’s office or 
outpatient setting. Complications that occur during hospitalization are AEs. If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious. When in doubt as to whether “hospitalization” occurred or was necessary , the 
AE should be considered serious.
Hospitalization for elective treatment of a preexisting condition that did not worsen 
from baseline is not considered an AE.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 80d.Results in persistent or significant disability/ incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance ,such as uncomplicated headache, nausea, v omiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), thatmay interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Is a suspected transmission via a Pfizer product of an infectious agent, pathogenic 
or non- pathogenic, is considered serious. 
The event may  be suspected from clinical s ymptoms or laboratory  findings indicating 
an infection in a participant exposed to a Pf izer product. The terms “suspected 
transmission” and “transmission” are considered sy nony mous. These cases are 
considered unexpected and handled as serious expedited cases b y pharmacovigilance 
personnel. Such cases are also considered for reporting as prod uct defects, if 
appropriate.
g.Other situations:
Medical or scientific judgment should be exercised by the investigator in deciding 
whether SAE reporting is appropriate in other situations, such as significant
medical events that may  jeopardize the particip ant or may  require medical or 
surgical intervention to prevent one of the other outcomes listed in the above 
definition. These events should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or
convulsions that do not result in hospitalization, or development of drug 
dependency  or drug abuse.
10.3.3. Recording/Reporting and Follow -Up of AE sand/or SAE sDuring the Active 
Collection Period 
AE and SAE Recording /Reporting
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAE son the CT SAE Report Form to Pfizer Safet ythroughout the active 
collection period . These requirements are delineated for 3 types of events: (1) SAEs; (2) 
nonserious AEs ; and (3) exposure to the study  intervention under stud y during pregnancy  
or breastfeeding, and occupational exposure. 
It should be noted that the CT SAE Report Form fo r reporting of SAE information is not 
the same as the AE page of the CRF. When the same data are collected, the forms must be 
completed in a consistent manner. AEs should be recorded using concise medical 

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 81terminology  and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to Pfizer 
Safety Within 24 Hours 
of Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeeding, All AEs or SAEs 
associated with exposure 
during pregnancy  or 
breastfeeding
Note:   Instances of EDP or 
EDB not associated with an 
AE or SAE are not 
captured in the CRF.All instances of EDP are 
reported (whether or not 
there is an associated 
SAE)*
All instances of EDB are 
reported (whether or not 
there is an associated 
SAE). **
Environmental or 
occupational exposure to 
the product under stud y to 
a non -participant (not 
involving EDP or EDB).None. Exposure to a study 
non-participant is not 
collected on the CRF.The exposure (whether or 
not there is an associated 
AE or SAE) must be 
reported.***
*EDP (with or without an associated AE or SAE): any pregnancy information is reported to 
Pfizer Safety using CT SAE Report Form and EDP Supplemental Form; if the EDP is 
associated with an SAE, then the SAE is reported to Pfizer Safety using the CT SAE Report 
Form. 
** EDB is reported to Pfizer Safety using the CT SAE Report Form which w ould also include 
details of any SAE that might be associated w ith the EDB. 
***Environmental or Occupational exposure: AEs or SAEs associated with occupational exposure 
are reported to Pfizer Safety using the CT SAE Report Form. 
When an AE or SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospital progress notes, laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE or SAE information in the CRF.
It is notacceptable for the investigator to send photocopies of the participant’s 
medical records to Pfizer Safety  in lie u of completion of the CT SAE Report 
Form /AEor SAE CRF page.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 82There may  be instances when copies of medical records for certain cases are 
requested b y Pfizer Safety .In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copies of the medical 
records before submission to Pfizer Safety .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE or SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: Asympto matic or mild sy mptoms; clinical or diagnostic observations only ; 
intervention not indicated.
Moderate: Minimal, local or noninvasive intervention indicated; limiting age -
appropriate instrumental ADL. Instrumental ADL refers to preparing meals, 
shopping for groceries or clothes, using the telephone, managing money , etc. 
Severe: Severe or medically  significant but not immediately  life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling, limiting self 
care ADL. Self care ADL refers to bathing, dressing and undressing, feeding self, 
using the toilet, taking medications, and not bedridden. 
An event is defined as “serious” when it meets at least 1 of the predefined 
outcomes as described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE or SAE. The investigator will use clinical 
judgment to determine the relationship.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration
,will be considered and investigated.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 83The investigator will also consult the IB and/or product information, for marketed 
products, in his/her assessment.
For each AE or SAE, the investigator must document in the medical notes th
at 
he/she has reviewed the AE or SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor . However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the sponsor .
The investigator may  change his/her opinion of causality  in light of follow -up 
information and send a nSAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the
event, then the event will be handled as “related to study  intervention ” for reporting 
purposes, as defined b y the sponsor . In addition, if the investigator determines that 
an SAE is associated with study  procedures, the investigator must record this 
causal relationship in the source documents and CRF, and report such an 
assessment in the dedicated section of the CT SAE Report Form and in accordance 
with the SAE reporting requirements.
Follow -Up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations, as medically  indicated or as requested by  the 
sponsor ,to elucidate the nature and/or causalit y of the AE or SAE as full y as 
possible. This may  include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare providers .
If a participant dies during participation in the study or during a recognized 
follow -up period, the investigator will provide Pfizer Safet y with a cop y of any 
postmortem findings, including histopathology .
New or updated information will be recorded in the originally  submitted 
documents .
The investigator will submit any  updated SAE data to the sponsor within 24 hours 
of receipt of the information.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 8410.3.4. Reporting of SAEs
SAE Reporting to Pfizer Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to Pfizer Safety will be the 
electronic data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool ( see next section) to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data
become available.
After the stud y is completed at a given site, the electronic data colle ction tool will 
be taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to Pfizer Safety  by telephone.
SAE Reporting to Pfizer Safety via CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to Pfizer Safety .
In circumstances when the fac simile is not working , notification by  telephone is 
acceptable with a cop y of the CT SAE Report Form sent by  overnight mail or 
courier service.
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated reporting 
time frames.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 8510.4. Appendix 4: Contraceptive and Barrier Guidance 
10.4.1. Male Particip ant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for at least 28daysafter the last dose of stud y intervention.
Refrain from donating sperm.
PLUS either :
Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual lifesty le (abstinent on a long -term and persistent basis) and 
agree to remain abstinent. 
OR
Must agree to use a male condom when engaging in any  activity  that allows for 
passage of ejaculate to another person.
In addition to male condom use, a highl y effective method of contraception may be 
considered in WOCBP partners of male participants (refer to the list of highly  effective 
meth ods below in Section 10.4.4 ).
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is eligible to participate if she is not pregnant or breastfeeding and is not 
a WOCBP (see definitions below in Section 10.4.3).
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed 
before the first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following:
Documented h ysterectomy ;
Documented bilateral salpingectomy ;
Documented bilateral oophorectom y.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 86For individuals with permanent infertility  due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion 
should be applied to determining study  entry .
Note: Documentation for any  of the above categories can come from the site 
personnel’s review of the participant’s medical records, medical examination, or 
medical history  interview. The method of documentation should be recorded in the 
participant’s medical record for the stud y.
2.Postmenopausal female .
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. In addition :
A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years old andnot using hormonal 
contraception or HRT. 
A female on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestrogen hormonal highly effective contraception methods 
if they  wish to continue their HRT during the study. Otherwise, they  must 
discontinue HRT to allow confirmation of postmenopausal status before study  
enrollment.
10.4.4. Contracepti onMethods
Contraceptive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
Highly Effective Methods That Have Low User Dependency 
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device.
3.Intrauterine hormone -releasing s ystem.
4. Bilateral tubal occlusion (eg, bilateral tubal ligation).
5.Vasectomized partner.
A vasectomized partner is a highl y effective contraceptive method provided that 
the partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed. If not, an additional highl y effective method of contraception 
should be used. The spermatogenesis cy cle is approximately  90 day s.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 87Highly Effective Methods That Are User Dependent 
1.Combined (estrogen- and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation:
Oral;
Intravaginal;
Transdermal;
2.Progestogen -only hormone contraception associated with inhibition of ovulation:
Oral;
Injectable.
3.Sexual abstinence:
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention. The reliability  of sexual abstinence needs to be 
evaluated in relation to the duration of the stud y and th e preferred and usual 
lifesty le of the participant.
One of the following effective barrier methods must be used in addition to the highl y 
effective methods listed above that are user dependent:
Male or female condom with or without spermicide;
Cervical cap , diaphragm, or sponge with spermicide;
A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods).

PF-07081532
Protocol C3991003Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 88 
 
 
 
 
 
 
 
 
 
 
 CCI
PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 8910.6. Appendix 6: Liver Safety: Suggested Actions and Follow -Up Assessments
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerators,” while those who show transient liver injury  but adapt 
are termed “adaptors.” In some participant s, transaminase elevations are a harbinger of a 
more serious potential outcome. These participant s fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as DILI. 
Participant s who experience a transaminase elevation above 3 ×ULN should be monitored 
more frequently  to determine if they  are “adaptor s” or are “susceptible.”
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations (>2 ×
ULN) b y several days or weeks. The increase in TBili ty picall y occurs while AST/ALT is/are 
still elevated above 3 ×ULN (ie, AST/ALT and TBili values will be elevated within the same 
laboratory sample). In rare instances, by  the time TBili elevations are detected, AST/ALT 
values might have decreased. This occurrence is still regarded as a potential DILI. Therefore, 
abnormal elevations in either AST OR ALT in addition to TBili that meet the criteria 
outlined below are considered potential DILI (assessed per Hy’s law criteria) cases and 
should alway s be considered important medical events, even before all other possible causes 
of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing conditions. Participant s who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  value s:
Participant s with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participant s with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values abo ve the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).
Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. 

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 90The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal results. This evaluation should 
include laboratory tests, detailed history , and physical assessment. 
In addition to repeating measurements of AST and AL T and TBili for suspected Hy ’s law
cases , additional laboratory  tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, total bile acids, and alkal ine phosphatase. Consideration should also be given 
to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporaneous analy ses at the time of the recognized initial 
abnormalities to determine etiology . A detailed history , including relevant information, such 
as review of ethanol, acetaminophen /paracetamol (either by  itself or as a coformulated 
product in prescription or over -the-counter medications) , recreational drug, or supplement 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
with a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collecte d. Further testing for acute 
hepatitis A, B, C, D, and E infection ,liver imaging (eg, biliary  tract) ,and collection of serum 
sample s
for acetaminophen/paracetamol drug and/or protein adduct levels may be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigatio ns have been received and have excluded an alternative etiology .

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 9110.7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings T hat May Q ualify as AEs
Marked sinus bradycardia (rate <40 bpm) lasting minutes.
New PR interval prolongation >280 ms ec.
New prolongation of QTcF to >480 ms ec(absolute) or by60msecfrom baseline .
New -onset atrial flutter or fibrillation, with controlled ventricular response rate: ie, 
rate<120 bpm .
New -
onset typeI second - degree (Wenckebach) AV block of >30 seconds’
duration.
Frequent PVCs, triplets , orshort intervals (<30 seconds) of consecutive ventricular 
complexes .
ECG Findings T hat May Q ualify as SAEs
QTcF prolongation >500 ms ec.
New ST -Tchanges suggestive of myocardial ischemia .
New -onset l eft bundle branch block (QRS >120 msec).
New -onset right bundle b ranch block (QRS >120 msec).
Symptomatic bradycardia .
Asystole:
In awake, s ymptom -free patients in sinus rhy thm, with documented periods of 
asystole 3.0 seconds or any  escape rate <40 bpm, or with an e scape rh ythm 
that is below the AV node ; 
In awake, s ymptom -free patients with atrial fibrillation and brad ycardia with 1 
or more pauses of at least 5 seconds or longer ; 
Atrial f lutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained s upraventricular tachycardia (rate >120 bpm) (“sustained ”= short 
duration with relevant symptoms or lasting >1 minute).

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 92Ventricular r hythms >30 seconds’ duration, including idioventricular rhy thm ( heart 
rate <40 bpm), accelerated idiov entricular rh ythm (HR 40 bpm to <100 bpm), and 
monomorphic/poly morphic ventricular tach ycardia (HR >100 bpm (such as
torsades de pointes) ).
Type IIsecond -degree (Mobitz II)AVblock.
Complete (third
-degree) heart block.
ECG Findings T hat Q ualify as SAEs
Change in pattern suggestive of new m yocardial infarction .
Sustained ventricular t achy arrhy thmias (>30 seconds ’duration) .
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion .
Ventricular fibrillation/ flutter .
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience .
The enumerated list of major events of potential clinical concern are recommended as “alerts” or 
notifications from the core ECG laboratory to the investigator and Pfizer study team, and not to be 
considered as all inclusive of what to be reported as AEs/SAEs.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 9310.8. Appendix 8: Prohibited Concomitant Medica tions That May Result inDDI
The prohibited concomitant medications listed below should not be taken wit h PF-07081532
for the period of time at least equal to the required washout period listed in the table, and 
throughout the conduct of the study . 
The Pf izer study  team is to be notified of any  prohibited medications taken during the study . 
After consulting with the sponsor, the investigator will make a judgement on the ongoing 
participation of an y participant with prohibited medication use during the stud y.
This list of drugs prohibited for potential DDI concerns with the IMP may  be revised during 
the course of the study  with written notification from sponsor, to include or exclude specific 
drugs or drug categories for various reasons ( eg, emerging DDI results for the IMP, 
availability  of new information in literature on the DDI potential of other drugs). 
This is not an all -inclusive list. Site staff s
hould consult with the sponsor or designee with 
any questions regarding potential DDI.
Drug Category Drugs (Therapeutic Class) Washout Period 
Requirement Prior to the 
First D ose of St udy 
Intervention
CYP3A 
Inhibitor 
(strong)Boceprevir (Antiviral),
Ceritinib (Kinase Inhibitor),
Clarithromycin (Antibiotic),
Cobicistat (Pharmacokinetic Enhancer),
Conivapta n (Diuretic),
Danoprevir and Ritonavir (Antiviral),
Elvitegravir and Ritonavir (Treatment of 
AIDS),
Grapefruit juice (Food Product),
Idelalisib (Kinase Inhibitor),
Indinavir (Protease Inhibitor),
Indinavir and Ritonavir (Protease Inhibitor),
Itraconazole (Antifungal),
Ketoconazole (Antifungal),
LCL161 (Cancer Treatment),
Lopinavir and Ritonavir (Protease Inhibitor),
Mibefradil (Calcium Channel Blocker),
Mifepristone (Antiprogestin),
Nefazodone (Antidepressant),
Nelfinavir (Protease Inhibitor),
Posaconazole (Antifungal),
Ribociclib (Kinase Inhibitor),
Ritonavir (Protease Inhibitor),
Saquinavir (Protease Inhibitor),
Saquinavir and Ritonavir (Protease Inhibitor),
Telaprevir (Antiviral),
Telithromycin (Antibiotic),5 half -lives plus 14 days

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 94Drug Category Drugs (Therapeutic Class) Washout Period 
Requirement Prior to the 
First D ose of St udy 
Intervention
Tipranavir and Ritonavir (Protease Inhibitor),
Troleandomycin (Antibiotic),
Tucatinib (Kinase Inhibitor),
Viekira Pak (Antiviral),
Voriconazole (Antifungal)
CYP3A 
Inducer 
(strong)Apalutamide (Antiandrogen),
Avasimibe (Antilipemic),
Carbamazepine (Anticonvulsant),
Enzalutamide (Antiandrogen),
Ivosidenib (Cancer Treatment),
Lumacaftor (Cystic Fibrosis Treatment),
Mitotane (Antineoplastic),
Phenobarbital (Anticonvulsant),
Phenytoin (Anticonvulsant),
Rifampin (Antibiotic),
Rifapentine (Antibiotic),
St. John’s wort extract (Herbal Medication)5 half -lives plus 14 days
OATP 
(1B1/1B3) 
InhibitorAtazanavir and Ritonavir (Protease Inhibitor),
Clarithromycin (Antibiotic),
Cyclosporine (Immunosuppressant),
Erythromycin (Antibiotic),
Gemfibrozil (Fibric Acid Derivative),
Lopinavir and Ritonavir (Protease Inhibitor),
Rifampin (Antibiotic),
Simeprevir (Antiviral)2 weeks or 5 half -lives,
whichever is longer
CYP2C19 
SubstrateBMS -823778 (Diabetes Treatment),
Clobazam (Benzodiazepine),
Clopidogrel (Antiplatelet),
Diazepam (Benzodiazepine),
Gliclazide (Sulfonylurea),
Hexobarbital (Hypnotic –Sedative),
Lansoprazole (Proton Pump Inhibitor),
Mephobarbital (Anticonvulsant),
Omeprazole (Proton Pump Inhibitor),
Pantoprazole (Proton Pump Inhibitor),
Proguanil (Antimalarial),
Rabeprazole (Proton Pump Inhibitor),
S-mephenytoin (Anticonvulsant),
Tilidine (Treatment of Pain & Inflammation),
Voriconazole (Antifungal)2 weeks or 5 half -lives,
whichever is longer
Investigators should consult the SRSD for active comparator for inform ation regarding 
medication that is prohibited for concomitant use.
Investigators should consult the product label for any  other medication used during the study  
for information regarding medication that is prohibited for concomitant use. 

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 9510.9. Appendix 9: Prohibited Medications Not Permitted From S creening
Drug class/Name Duration Not Permitted 
from S creening
TZDs: eg, pioglitazone; rosiglitazone Within 3 Months of 
Screening Subcutaneously administered agents for glycemic control: eg, insulin,
exenatide, liraglutide, pramlintide
Other oral anti -diabetic medications:
Sulfonylureas: eg, acetohexamide, chlorpropamide, 
tolazamide, tolbutamine;
Glimepiride, glipizide, glyburide;
Meglitinide analogues, eg, repaglinide, nateglinide;
DPP-4i eg, sitagliptin, saxagliptin;
Vildagliptin;
α-glucosidase inhibitors, eg, acarabose, miglitol;
SGLT2 inhibitors, eg, canagliflozin.Within 4 Weeks of 
Screening
Systemic glucocorticoids, eg, prednisone, dexamethasone, 
triamcinolone, budesonide, betamethasone. Note: As an exception, 
steroid -containing inhalers, nasal sprays, and topical formulations are 
permitted.
Immunosuppressants , eg, cyclosporine and tacrolimus.
Appetite- or weight -modifying medications, including non -
prescription or herbals.
Pharmacological agents with approved indication for weight loss, eg, 
orlistat and sibutramine.
(Medical -grade) marijuana, regardless of medical indication.
Anti-psychotic medications, eg olanzapine, risperidone.
Antidepressant medications, eg tricycl ic agents, selective serotonin 
reuptake inhibitors, and serotonin/norepinephrine reuptake inhibitors.
Coumarin -type anticoagulants or other anticoagulants (eg, 
dabigatran).
Anticonvulsants, if prescribed for a seizure disorder.
Opioids.
Antiarrhythmics.
Non-selective β -blockers.
Thiazide diuretics >25 mg per day.
Sympathomimetic agents.

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 9610.10. Appendix 10: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
%CV percent coefficient of variation
Abs absolute
ADL activities of daily  living
AE adverse event
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC area under the concentration -time curve
AUC inf area under the concentration -time curve from time 0 to infinity
AUC last area under the concentration -time profile from time 0 to the time of 
the last quantifiable concentration
AUC (0-4) area under the curve from 0 to 4 hours 
AUC 24 area under the concentration -time curve over 24 hours
AUC inf area under the concentration -time curve to infinity
AV atrioventricular
BBS Biospecimen Banking S ystem
BCRP Breast Cancer Resistance Protein
BMI body  mass index
BP blood pressure
Bpm beats per minute
BUN blood urea nitrogen
cAMP 3’-5’-cyclic adenosine monophosphate
CFB change from baseline
CFR Code of Federal Regulations
CI confidence interval 
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CL clearance
CL/F apparent clearance
CL p plasma clearance
Cav average concentration
Cmin minimum observed concentration
Cmax maximum observed concentration
CO 2 carbon dioxide (bicarbonate)
CONSORT Consolidated Standards of Reporting Trials
COVID -19 coronavirus disease 2019
CRF case report form
CRO contract research organization
CRU clinical research unit
CSR Clinical Study  Report
CT clinical trial

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 97Abbreviation Term
CV co-efficient of variation
CYP cytochrome P450
DCT data collection tool
DDI drug-drug interaction
DILI drug-induced liver injury
DMC Data Monitoring Committee
DPP-4i dipeptidy l peptidase -4 inhibitors 
DU dispensable unit
EC ethics committee
ECC emergency  contact card
ECG electrocardiogram
eCRF electronic case report form
EDB exposure during breastfeeding
EDP exposure during pregnancy
EDR extemporaneous dispensing record
eGFR estimated glomerular filtration rate
EMA European Medicines Agency
EU European Union
EudraCT European Clinical Trials Database
FPG fasting plasma glucose
FPI fasting plasma insulin
FSBG fingerstick blood glucose
FSH follicle -stimulating hormone
FU follow -up
GCP Good Clinical Practice
GFR glomerular filtration rate
GGT gamma -glutamy l transferase
GI gastrointestinal
GLP-1 glucagon -like peptide -1 
GLP-1R glucagon -like peptide -1 receptor
H hour
HbA1c Glycated hemoglobin
HBcAb hepatitis B core antibod y
HBsAb hepatitis B surface antibody  
HBsAg hepatitis B surface antigen
HCVAb hepatitis C antibody
HDL high densit y lipoprotein
HIV human immunodeficiency virus
HOMA -IR homeostatic model assessment of insulin resistance
HR heart rate
HRT hormone replacement therap y
IB Investigator’s Brochure
ICD informed consent document

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 98Abbreviation Term
ICH International Council for Harmonisation of Technical Requirements 
for Pharmaceuticals for Human Use
ID identification
IND Investigational New Drug
INR international normalized ratio
IP investigational product 
IPAL Investigational Product Accountability  Log
IRB Institutional Review Board
IRT Interactive Response Technology
IV intravenous(l y)
IVGTT intravenous glucose tolerance test
K2EDTA dipotassium ethy lenediaminetetraacetic acid
kel terminal phase rate constant
kg kilogram
Ki mean binding inhibition constant
LBBB left bundle branch block
LDL low density  lipoprotein
LFT liver function test
Loge natural logarithm with the base e
MATE multi -drug and toxin extrusion protein 
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MDG mean dail y glucose
MEN2 multiple endocrine neoplasia sy ndrome type 2
mg/dL milligram(s) per deciliter
µmol/L micromole per liter
MDRD modification of diet in renal disease 
min minute; minimum
MMTT mixed meal tolerance test
msec millisecond
MTC medullary  thyroid cancer
MTD maximum tolerated dose
MDR1 multidrug resistance protein 1
N/A Not applicable
N total number
NC not calculated
NHP non-human primate 
nM nanomolar
NOAEL no observed adverse effect level
NSAID non-steroidal anti -inflammatory  drug
OAT organic anion transporter 
OATP organic anion transporting pol ypeptide

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 99Abbreviation Term
OCT organic cation transporter
PD pharmacod ynamic(s)
P-gp P-glycoprotein
PI Principal Investigator
PK pharmacokinetic(s)
PT prothrombin time
PTR peak -to-trough ratio 
PVC premature ventricular contraction
QD once daily
QT duration of ventricular depolarization and subsequent repolarization. 
Duration resides between beginning of QRS complex to end of the 
T wave
QTc corrected QT
QTcF QTc corrected using Fridericia’s formula
qual qualitative
Rac accumulation ratio based on AUC (observed)
Rac,Cmax Cmaxaccumulation ratio 
RBC red blood cell
SAE serious adverse event
SAP Statistical Analy sis Plan
SCr serum creatinine
SD standard deviation
SGL T2 sodium -glucose cotransporter -2
SoA schedule of activities
SOP standard operating procedure
SRSD single reference safet y document
SS steady  state
SSID single subject identifier
SToD Study  Team on Demand
SUSAR Suspected Unexpected Serious Adverse Reaction
t½ terminal phase half life
T2DM type 2 diabetes mellitus
T4 free th yroxine
TBD to be determined
TBA total bile acids
TBili total bilirubin
TEAE treatment -emergent adverse event
THC tetrah ydrocannabinol
Tmax time to reach C max
TSH thyroid stimulating hormone
TZD thiazolidinedione
UGT uridine 5'-diphospho -glucuronos yltransferase
ULN upper limit of normal

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 100Abbreviation Term
US United States
Vss steady -state volumes of distribution 
Vz/F apparent volume of distribution for extravascular dosing
WBC white blood cell
WOCBP woman/women of childbearing potential
WONCBP woman/women of non -childbearing potential

PF-07081532
Protocol C3991003
Final Protocol, 21 October 2021
PFIZER CONFIDENTIAL
Page 10111.REFERENCES
1. Orskov C, Holst JJ, Knuhtsen S, et al. Glucagon -like peptides GL P-1 and GL P-2, 
predicted products of the glucagon gene, are secreted separatel y from pig small intestine 
but not pancreas. Endocrinology .1986;119(4):1467-75.
2. Krey mann B, Williams G, Ghatei MA, et al. Glucagon -like peptide-1 7- 36: a 
physiological incretin in man. Lancet .1987;2(8571):1300
-4.
3. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon- like peptide 1 inhibition of 
gastric empt ying outweighs its insulinotropic effects in healthy  humans. Am J Phy siol.
1997;273(5):E981-8.
4. Flint A, Raben A, Astrup A, et al. Glucagon -like peptide 1 promotes satiet y and 
suppresses energy  intake in humans. J Clin I nvest .1998;101(3):515 -20.
5. I DF Diabetes Atlas 8thEdition . Available from: .http://www.idf.org/diabetesatlas.
Accessed: 20 September 2021 .
6. Menke A, Casagrande S, Geiss L , et al. Prevalence of and t rends in diabetes among 
adults in the United States, 1988 -2012. JAMA .2015;314(10):1021 -9.
7. Hu FB. Globalization of diabetes: the role of diet, lifesty le and genes. Diabetes Care .
2011;34(6):1249 -
57.
8. DeFronzo RA. From the triumvirate to the omnious octet: a new paradigm for the 
treatment of t ype 2 diabetes mellitus. Diabetes .2009;58(4):773 -95.
9. Stratton I M, Adler AI, Neil HAW, et al. Association of gl ycaemia with macrovascular 
and microvascular complications of ty pe 2 diabetes (UKPDS 35): prospective 
observational study . BMJ .2000;321(7258):405
-12.
10. Drucker, DL. The ascending GLP -1 road from clinical safet y to reduction of 
cardiovascular complications. Diabetes .2018;67:1710-9.
11. Lorenz M, Lawson F, Owens D, et al. Differential effects of glucagon- like peptide -1 
receptor agonists on heart rate. Cardiovasc Diabetol .2017;16(1) :6.
12. Victoza (liraglu tide) US prescribing information . Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022341s031lbl.pdf.
Accessed: 17 September 2021.
13. American Diabetes Association. Pharmacologic approaches to glycemic treatment: 
standards of m edical care in diabetes —2019 American Diabetes Association. Diabetes 
Care .2019; 42 (Suppl.1):S90 -S102.
14. Wallace TM, Lev y JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes 
Care .2004;27(6)(Jun):1487
-95.
